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Abstract
Postoperative breastfeeding recommendations for lactating mothers by anesthesia providers
are inconsistent and often inaccurate. Inappropriate recommendations have led to withholding
of breastmilk to the infant, unnecessary disposal of breastmilk, surgical delay, exposure of an
infant to high levels of drugs in breastmilk, and early cessation of breastfeeding. The purpose of
the scholarly project was to develop a set of evidenced-based practice guideline
recommendations and a proposed implementation plan for anesthesia providers to use in
support of breastfeeding mothers who recover from surgery. Many studies in the literature
indicate that there are inconsistencies in postoperative breastfeeding recommendations by
anesthesia providers. When postoperative breastfeeding guidelines were implemented,
anesthesia staff were more likely to recommend breastfeeding in the immediate postoperative
period and feel more confident in their recommendation. In addition, there were fewer
preventable delays in breastfeeding resumption and fewer neonatal safety events. Tools from
the Johns Hopkins Nursing Evidence-Based Practice model were used to guide a systematic
literature review, synthesize evidence, and develop an implementation plan. The literature
review included the safety of commonly used perioperative medications in the lactating
mother. Overall, almost all medications used in the perioperative period are safe to use in
lactating mothers, except for codeine, meperidine, tramadol, diazepam, and hydromorphone.
As part of this project, a guideline implementation plan for future use by anesthesia providers
was developed and proposed to occur over 11 months. Additionally, a ten-question knowledge
and confidence assessment regarding breastfeeding recommendations was proposed to be
distributed to all anesthesia providers (e.g., Anesthesiologists and Certified Registered Nurse
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Anesthetist [CRNAs]) prior to guideline implementation, one month after implementation, and
six months after implementation. The anticipated statistical analysis plan for knowledge and
confidence outcome data is recommended to utilize the one-way analysis of variance (ANOVA)
test. The clinical importance of this scholarly project is that the project’s proposed clinical
practice guidelines may help to increase anesthesia provider knowledge and confidence in
providing effective postoperative education concerning the safety and compatibility of certain
anesthesia medications and continued practices of breastfeeding patients following surgery.
Keywords: lactation, anesthesia, guidelines, safety, breastfeeding, post-surgical
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Final Scholarly Project
Problem Identification
The number of breastfeeding women who require anesthesia, both during labor and for
non-childbirth related procedures, has increased throughout the United States (Martin et al.,
2018). Anesthesia providers need to be aware of the implications of administered medications
in the infant of the lactating mother however, many studies indicate that some patients and
surgical staff have an inaccurate understanding of the safety of breastfeeding after anesthesia
(Moore et al., 2021; Reith et al., 2018). Staff recommendations given to nursing mothers are
often inconsistent and can lead to unnecessary and prolonged interruptions in breastfeeding,
disposal of breastmilk, and early breastfeeding cessation (Mitchell et al., 2020). In addition, lax
recommendations may expose the infant to dangerous levels of medications in the breastmilk
(Gilder et al, 2021).
The facility of interest, a large urban hospital with a busy labor and delivery department,
does not have a policy or practice guideline regarding breastfeeding after maternal anesthesia.
Therefore, anesthesia providers’ recommendations for breastfeeding may be inconsistent or
might not be aligned to up to date and best evidence. Lack of standardized breastfeeding
protocols can lead to withholding of breastmilk to the infant, unnecessary disposal of
breastmilk, surgical delay, exposure of an infant to high levels of drugs in breastmilk, and early
cessation of breastfeeding (Gilder et al., 2021; Mitchell et al., 2020). This facility of interest may
benefit from the implementation of an evidence-based guideline for breastfeeding after
anesthesia.
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Literature reviewing the implementation of a protocol for breastfeeding after
anesthesia is rare. Moore et al. (2021), describes the implementation of a post anesthesia
breastfeeding protocol at a mid-sized military hospital. A literature review was performed to
determine best practice for common medications used in anesthesia. Information was obtained
from peer reviewed articles and LactMed, a database that contains information on the transfer
and safety of medications in breastmilk (LactMed, 2018). This knowledge was presented to staff
in a lecture and developed into a unit policy. Results from this study indicate that personnel
were more likely to recommend immediate breastfeeding after anesthesia and feel more
confident in their recommendation (Moore et al., 2021). Another article by Folh and Stephens
(2019) describes the implementation of a post-anesthesia breastfeeding program at a large,
academic level 1 trauma center. Educational materials were created and distributed to all
perioperative staff and lactation support procedures were implemented. After the
implementation of this program, findings indicated that there were no preventable delays in
the resumption of breastfeeding and there were fewer neonatal safety events (Folh &
Stephens, 2019).
Professional anesthesia organizations, such as the American Society of Anesthesiologists
(ASA)(2019), have released statements on the importance of safely resuming breastfeeding
after anesthesia. Drug safety of commonly used medications in the perioperative period was
described using the relative infant dose (RID), the infant’s weight based daily dose through
breastmilk divided by the mother’s weight based daily dose. RID less than 10% is generally
considered safe (Hendrickson & McKeown, 2012). The American Association of Nurse
Anesthesiology (AANA) presents general concepts regarding breastfeeding after maternal
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anesthesia including “A nursing mother should be allowed to breastfeed as soon as she is
awake and aware after general anesthesia” (AANA, n.d.).
Background/Significance
Over 75% of laboring women receive some form of anesthesia including epidural, spinal,
and general anesthesia (Butwick et al., 2018; Ring et al., 2021). In addition, many women who
are breastfeeding require anesthesia for non-pregnancy related operations. Most medications
used in anesthesia will cross into the breastmilk but are harmless to the infant (Oliveira et al.,
2019). Generally, breastfeeding may resume after maternal anesthesia once a mother is alert
and able to breastfeed independently (Mitchell et al., 2020). However, some medications can
cause neonatal respiratory depression or sedation. Depending on anesthesia medications
administered, mothers may resume breastfeeding immediately after surgery or may have to
dispose of their breastmilk.
Exclusive breastfeeding for six months after birth is considered the gold standard for
infant nutrition by all major health organizations (WHO, 2018a; CDC, 2021; AAP, 2012).
Breastfeeding provides complete and inexpensive nutrition to infant. Breastfeeding offers many
benefits to infant including decreased risk of infection, obesity, and sudden infant death
syndrome. Breastfeeding also benefits the mother by increasing postpartum weight loss and
decreasing the risk of type 2 diabetes mellitus, ovarian cancer, and breast cancer (Kelsey, 2016).
Inappropriate recommendations for breastfeeding mothers after anesthesia can lead to
withholding of breastfeeding, “pumping and dumping “, or adverse neonatal affects.
Withholding breastfeeding may cause the mother to develop mastitis, breast engorgement, and
decreased milk supply. Disposal of breastmilk after anesthesia is mostly unneeded, can be
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costly, and can contribute to unneeded maternal stress. If medications are utilized that are not
safe for the lactating woman and breastfeeding is resumed immediately postoperatively,
infants may suffer sedation, CNS depression, or even death.
The current literature indicates a need for postoperative breastfeeding protocols and
education in perioperative units. Implementation of these protocols may increase
breastfeeding outcomes and decrease adverse events for both the mother and infant.
PICO Question
In anesthesia providers who provide care to lactating mothers (P), how does using an
established postoperative breastfeeding guideline (I) in comparison to current practice (C)
affect provider knowledge and confidence in providing postoperative breastfeeding
recommendations (O)?
Project Objectives
•

Perform a systematic literature review to create evidence-based practice guidelines for
anesthesia providers to make recommendations for breastfeeding after maternal
anesthesia.

•

Use the Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) Model to develop a
guideline implementation plan

•

Determine how to measure outcomes from the postoperative breastfeeding guideline
implementation.

•

Increase anesthesia provider knowledge of the implications of commonly used
medications in anesthesia on breastfeeding.
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Increase anesthesia provider confidence in providing postoperative breastfeeding
recommendations.

•

Use the continuous cycle of the JHNEBP model for guideline adjustment if initial
outcomes are poor.

Purpose
The purpose of the scholarly project was to develop a set of evidenced-based practice
guideline recommendations and a proposed implementation plan for anesthesia providers to
use in support of breastfeeding mothers who recover from surgery. Anesthesia providers will
use this guideline to direct safe breastfeeding practices before and after anesthesia
administration.
Literature Review
To establish current practices and knowledge of breastfeeding after anesthesia, a
systematic literature review was performed using the Cumulative Index to Nursing and Allied
Health Literature (CINAHL), MEDLINE, PubMed, and Cochrane Library. Search terms used
included “breastfeeding or breast-feeding or lactation or lactating or breast milk or mother’s
milk or colostrum or suckling” and the generic and brand name, if applicable, of commonly used
perioperative medications including propofol, etomidate, ketamine, thiopental,
dexmedetomidine, fentanyl, sufentanil, alfentanil, remifentanil, morphine, meperidine,
codeine, hydromorphone, tramadol, diazepam, midazolam, lorazepam, ketorolac, and
acetaminophen. Search expanders were applied to search for related words and equivalent
subjects. Articles were limited to the English language. Articles were analyzed using the
Research Evidence Appraisal and Non-Research Evidence Appraisal tool from the Johns Hopkins
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Nurse Evidence-Based Practice Model. The level of evidence (I-V) was determined by research
design and the evidence quality (A, B, or C) was determined by sample size, consistency of
results, thorough research process, and strong results. Descriptions of the articles selected for
this literature review can be found in Appendix A. As no human subjects participated in this
portion of this scholarly project, this project was exempt for Institutional Review Board
(Appendix B).
In total, 45 articles were used for the literature review. Because literature detailing
anesthesia and breastfeeding is rare, articles from as early as 1972 were included for review.
Articles obtained from the four research databases were reviewed and their sources were also
analyzed for relevance. There were two level I articles, four level II articles, 25 level III articles,
four level IV articles, and 10 level V articles. There were 21 articles with “A” evidence quality, 22
articles with “B” evidence quality, and two articles with “C” evidence quality.
In addition to utilizing research databases, Lactmed, a free and open access online drug
and lactation database, was used for medications without resulting articles. Lactmed is
operated by the National Institute of Health and uses a peer review panel to assess data validity
and currency (Lactmed, n.d.).
Lactation and Infant Pharmacokinetics
Most medications utilized in the perioperative period are safe to use for breastfeeding
mothers. However, each drug’s pharmacokinetic profile must be investigated before
administration. The safety of a medication in a nursing mother is determined by a multitude of
factors including the half-life of a medication, presence of active metabolites, dose, frequency
of administration, and the likelihood of drug transfer into breastmilk. Medications that are

BREASTFEEDING AFTER MATERNAL ANESTHESIA

10

unionized, have short half-lives, low molecular weight, low protein binding, and increased lipid
solubility are more likely to cross from the maternal circulation into breast milk (Lobkova &
Wolf, 2014). Drugs with high oral bioavailability are more likely to cause side effects in the
infant (Mitchell et al., 2020). In addition, large amounts and frequent doses of medications
increase the risk of an adverse reaction (Dalal et al., 2014).
Various characteristics of the infant may alter their susceptibility to maternal anesthesia
including gestational age at birth, chronological age, weight, and presence of physiological
derangements. Premature and newborn infants have decreased hepatic and renal metabolism,
thus prolonging the action of any drugs consumed. Infants with a history of apnea may be more
sensitive to drugs that decrease respiratory drive, such as benzodiazepines and opiates (ReeceStremtan et al., 2017). Infants with physiologic derangements may be more sensitive to
maternal medications (Moore et al., 2020).
The effect of maternal medications on infants is also determined by the volume of
breastmilk consumed by the infant and the infant’s weight. Breast milk may always be
expressed and used when the infant is older or diluted with breastmilk pumped prior to surgery
(Reece-Stremtan et al., 2017).
Drugs
Sedatives and Hypnotics.
Propofol (Diprivan).
Propofol is a gamma-aminobutyric acid (GABA)-A receptor agonist used often in the
perioperative period for induction and maintenance of anesthesia. In addition, propofol is used
for procedural sedation, nausea prevention and treatment, and medically induced comas. Many
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of the beneficial qualities of propofol, such as a low oral bioavailability and high protein
binding, make propofol less likely to enter breastmilk.
In the review of the literature, three sources indicated that propofol levels in breastmilk
are negligible. In a study by Nitsun et al. (2006), five lactating women who presented for
scheduled procedures requiring general anesthesia received 2.5 mg/kg of intravenous (IV)
propofol for induction. All breastmilk was expressed by pump and collected for 24 hours after
drug administration. An average total of 0.027% of the maternal propofol dose was collected in
the participants’ breastmilk over 24 hours. Because of the minimal amount of drug transfer into
milk and the low likelihood that the infant would have consumed the total volume expressed,
the authors recommend that the mother may resume breastfeeding as soon as she recovers
from general anesthesia. Struttman et al. (2010), recorded the amount of propofol in the
breastmilk of lactating mothers 90 and 300 minutes after an IV induction dose. Although the
values were increased in comparison to Nitsun et al., at 0.09% and 0.028% respectively,
theoretical amounts of propofol that would be consumed were still considered negligible.
Dailland et al. (1989) found that the levels of propofol in colostrum after use for both IV
induction and infusion doses during a general anesthetic for cesarean section were negligible in
comparison to the placental exposure that occurred during birth. After birth and breastfeeding,
propofol had minimal effects on the healthy newborn. Due to the low levels of propofol
excreted in the breastmilk after both induction and infusion doses and the low bioavailability of
propofol, there is a low risk of adverse effects from the use of IV propofol in the nursing
mother.
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Etomidate (Amidate).
Etomidate is a GABA-A receptor agonist used commonly for induction of general
anesthesia. Etomidate is commonly used in patients who require hemodynamic and respiratory
stability. Etomidate is a weak base that is moderately protein bound and rapidly metabolized.
The systematic review of the literature resulted in one study detailing etomidate
concentration in breastmilk. Esener et al. (1992), found that after an IV induction dose of 0.3
mg/kg of etomidate used for women undergoing cesarean section, levels of etomidate in the
colostrum were 79 ng/ml at 30 minutes and 16 ng/ml at two hours. Four hours after use,
etomidate was undetectable in colostrum. Because of the extremely low levels of IV etomidate
excreted into breastmilk, there is a low risk of adverse effects in the infant of a lactating
woman.
Ketamine (Ketalar).
Ketamine is a N-methyl-D-aspartate (NMDA) receptor antagonist used for induction of
general anesthesia, perioperative and postoperative analgesia, sedation of mechanically
ventilated patients in critical care areas, and treatment of psychiatric disorders. Ketamine also
has effects on opiate, monoamine, and GABA receptors (Wallach & Brandt, 2018). Ketamine
has high lipid solubility, low protein binding, low oral bioavailability, and produces a metabolite,
norketamine, that has 25% potency of ketamine.
This literature review resulted in two articles describing ketamine use in the lactating
mother. In the study by Gilder et al. (2021), patients in a resource received an average of 1.16
mg/kg of IV ketamine for induction and maintenance of general anesthesia. Although the
amount of ketamine in the breastmilk of these patients was not quantified, infants did not
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show increased weight loss, jaundice, poor breastfeeding, sleepiness, seizures, mortality or
long-term neurological damage when compared to a control group. The second study, recently
released results from a US clinical trial, is the first study to quantify ketamine and norketamine
in breastmilk. Wolfson et al. (2021) administered 0.5 mg/kg or 1 mg/kg of intramuscular (IM)
ketamine to four lactating women who presented for ketamine therapy for postpartum
depression. Bioavailability of IV and IM ketamine is similar, 100% and 95% respectively
(Clements et al., 1982). Expressed breast milk was obtained from participants at 0, 3, 6, 9, and
12 hours after administration. The highest accumulation in the participants’ breastmilk over 12
hours was 24 mcg of ketamine and 21 mcg of norketamine, leading to a relative infant dose of
0.8%. The findings from the above studies indicate that it is unlikely that IV ketamine will cause
adverse effects in the nursing infant however, the study by Wolfson et al. only included four
participants and has yet to be peer reviewed. There is further need of investigating the use of IV
ketamine in lactating woman in a study with a larger sample size.
Dexmedetomidine (Precedex).
Dexmedetomidine is a highly selective Alpha 2 adrenergic agonist used for the
prevention of emergence delirium and sedation of mechanically ventilated patients. Patients
who receive dexmedetomidine also maintain spontaneous respiration even at high doses
(Ramsay & Luterman, 2004). Dexmedetomidine is a highly protein bound drug with low
bioavailability.
The literature review resulted in three articles describing dexmedetomidine in
breastmilk. In a study by Dodd et al. (2021), a patient presented for an open craniotomy four
weeks postpartum. A dose of 45 micrograms (mcg) of IV Precedex was used for sedation,
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followed by an infusion at 0.7-1 mcg/kg/hr. Breastmilk was expressed twice during the
procedure and one and four hours postoperatively. The highest concentration of 89 pg/mL, an
extremely small dose, was found one hour after conclusion of the procedure. Yoshimura et al.
(2017) and Nakanishi et al. (2017) measured dexmedetomidine concentrations in the blood and
colostrum of women who presented for scheduled cesarean sections. The participants received
6 mcg/kg/hour of IV Precedex for ten minutes after cord clamping followed by a dose of 0.2-0.7
mcg/kg/hour until peritoneal closure. Six hours after Precedex administration, Yoshimura found
that the median plasma level was 19.7 pg/mL and the median colostrum level was 12.3 pg/mL,
leading to a M:P ratio of 0.76 and a relative infant dose of 0.034%. Nakanishi found that after
six hours, the mean plasma level was 18.2 pg/mL and the mean colostrum level was 15.1
pg/mL, leading to a M:P ratio of 0.62 and a relative infant dose of 0.05%. Due to the
pharmacokinetic characteristics of dexmedetomidine and the evidence found above, single
doses and short infusion of IV dexmedetomidine has a low risk of use in the lactating mother.
Further evidence is required for patients receiving dexmedetomidine as a long-acting
transfusion.
Opioids.
Fentanyl.
Fentanyl is a short acting synthetic opioid agonist that is commonly used for pain
control, sedation, and induction of general anesthesia. In terms of analgesic potency, Fentanyl
is about 100 times stronger than morphine. Fentanyl is a highly lipophilic drug with a short
duration of action and moderately high protein binding.
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Three articles were found regarding the safety of both epidural and intravenous
fentanyl in the breastfeeding mother. In a study performed by Nitsun et al. (2006), five lactating
women received 100 mcg of IV fentanyl for induction of general anesthesia for tubal ligation or
laparoscopic cholecystectomy. All breastmilk was collected for 24 hours and analyzed for
fentanyl concentration. The median amount of fentanyl found in the total breastmilk volume
was 0.024 mcg, 0.024% of the maternal dose. Steer et al. (1992) used 2 mcg/kg of IV fentanyl
for induction of general anesthesia for patients receiving a cesarean section or tubal ligation.
Serum and breastmilk were collected for 10 hours after administration. The highest fentanyl
concentration found in breastmilk, 0.45 ng/mL, was 45 minutes after administration. Lastly,
Goma et al. (2008), assessed fentanyl levels in breastmilk of patients who received 100-150 mcg
of epidural fentanyl or 50 mcg of IV fentanyl. The average concentration of fentanyl in the
breastmilk was 40 ng/mL for women who received epidurals and 19 ng/mL for women who
received IV fentanyl. All three studies obtained in this literature review indicate that there is a
low risk in using fentanyl as an IV induction dose or an epidural additive for nursing mothers.
Further investigation into the safety of fentanyl infusions in the nursing mother is warranted.
Morphine.
Morphine is a naturally occurring opioid agonist commonly used for pain control in the
perioperative period as well as an adjunct in neuraxial anesthesia. Morphine has low protein
binding, is hydrophilic, has low oral bioavailability, and has a moderate duration of action. Ten
percent of morphine is broken down into an active metabolite, morphine-6-glucuronide (M6G),
a hydrophilic substance. There is conflict in the scientific community regarding the safety of
morphine in the lactating mother.
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The literature review resulted in three articles, one randomized control trial and two
nonexperimental studies. Wittels et al. (1990), measured breastmilk concentrations of women
who received meperidine or morphine for postoperative analgesia through a patient-controlled
analgesic (PCA) pump. The highest average breastmilk concentration of morphine, 60 ng/mL,
was found 4 hours after morphine administration, however, M6G levels were not measured.
Wittels et al. (1997) assessed the alertness and orientation of infants of mothers who received
morphine or meperidine PCAs. Nursing infants of mothers who received morphine PCAs were
more alert and oriented than nursing infants of mothers who received meperidine PCAs and
bottle fed infants. Lastly, Boka et al. (2002) assessed the plasma and breastmilk concentrations
of both morphine and M6G of women who were on morphine PCAs. The highest mean
morphine concentration in the breastmilk was 34 ng/mL and the highest mean concentration of
M6G was 672 ng/mL. These studies indicate that using IV morphine for a short period of time
poses a low risk of harm to the nursing infant. However, because morphine does have an active
metabolite, using prolonged morphine infusion may result in a buildup of M6G, which has both
analgesic and ventilatory depressant effects (Stoelting, 2015).
Meperidine (Pethidine).
Meperidine is a synthetic opioid agonist that shares structural features with local
anesthetics and anticholinergics. Meperidine has about 1/10 of the analgesic potency of
morphine, has a moderate duration of action, and has an active metabolite, normeperidine.
Normeperidine is about half as potent as meperidine, has proconvulsant properties, and has a
prolonged elimination half- time of 15 hours (Stoelting, 2015).
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The review of literature resulted in four articles. Wittels et al. (1990) studied women
who used a meperidine or morphine PCA after cesarean section. The authors found that
women who received 1 mg/kg dose of meperidine followed by a 12.5 mg meperidine PCA with
a 6 minute lockout had an average peak breastmilk meperidine concentration of 1100 ng/mL at
2 hours after administration. Additionally, participants also had an average peak breastmilk
normeperidine concentration of 500 ng/mL at 3 hours after administration. Wittels et al.
(1990), also used a neonatal behavioral assessment scale (NBAS) to assess infants for alertness
and orientation. Neonates that were in the meperidine group consistently scored lower than
the neonates in the morphine group. In an additional study similar in design with a larger pool
of participants, Wittels et al. (1997) again found that patients of mothers receiving meperidine
scored lower on the NBAS. Al-Tamimi et al. (2011) investigated the concentration of both
meperidine and normeperidine in the breastmilk of women with meperidine PCAs after
cesarean section. The highest calculated mean infant dose of meperidine via breastmilk was 20
mcg/kg/day. The highest calculated mean infant dose of normeperidine via breastmilk was 22
mcg/kg/day. Participants in a study by Borgatta et al. (1997) received 25 mg of meperidine as
part of a general anesthetic for tubal sterilization. The peak average meperidine level was 176
ng/mL at one hour after administration.
There is disagreement throughout the literature of the use of meperidine in the
lactating mother. Although the mean levels of Pethidine in breastmilk in the above studies are
far below the maximum therapeutic dose of 1.5 mg/kg/day, levels of norpethidine were not
measured in all studies. Additionally, there was a statistically significant depression in behavior
in infants of mothers on meperidine PCAs. There is likely a low risk of a single dose of IV
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meperidine in the nursing mother, but more evidence is needed to determine the safety of
multiple doses.
Codeine.
Codeine is a weak opioid agonist once used commonly for postpartum mothers. Codeine
has low protein binding and high oral bioavailability. Most importantly, codeine is a prodrug
that is metabolized to morphine in the body by the enzyme CYP2D6. Morphine is responsible
for almost all the analgesic and central nervous depression (CNS) depressant effects of codeine.
Because mothers can have varying levels of CYP2D6, resulting and unpredictable morphine
levels may result. The review of the literature resulted in seven articles discussing the safety of
codeine in the nursing mother.
Much of the hesitance in the medical community to use codeine in the nursing mother
resulted from the “Toronto Case”, a case study by Madadi et al. (2007) that describes morphine
overdose in an infant of a woman taking codeine. Postmortem blood levels in the infant were
five times higher than a therapeutic concentration. The authors concluded that the mother was
an ultrarapid metabolizer of codeine, resulting in high morphine levels in her breastmilk and
consequently in her child. CYP2D6 ultrarapid metabolism can occur in up to 29% of the
population, leading the authors to recommend the avoidance of codeine in the nursing mother
(Madadi et al., 2007). Due to this occurrence, the U.S. Food and Drug Administration (FDA) and
American College of Obstetrics and Gynecology (ACOG) released statements of caution in the
use of codeine in the nursing mother.
Madadi et al. (2008) compared genetic and nongenetic characteristics of infants who
exhibited or did not exhibit CNS depression while nursing from mothers taking codeine. Almost
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25% of mothers reported CNS depression in their infants that resolved with the cessation of
breastfeeding or maternal codeine use. When infants exhibited CNS depression, mothers were
likely to exhibit CNS depression. Additionally, mothers of symptomatic infants consumed a 60%
higher dose than mothers of asymptomatic infants. Mothers of infants who exhibited CNS
depression were six times more likely to be ultrarapid metabolizers of CYP2D6.
Using data and characteristics from the Toronto case, Willmann et al. (2009) developed
a pharmacokinetic model to determine the exposure and clearance of morphine and codeine by
the infant of a nursing mother who is taking codeine. The authors determined that morphine
clearance was the most important determinant of morphine accumulation in neonates. Toxic
blood morphine levels in the neonate can be attained within four days of repeated maternal
codeine administration. The authors were unable to obtain infant blood levels equal to the
Toronto case while running a worst-case scenario on the pharmacokinetic model, an ultrarapid
metabolizer mother with an infant with minimal morphine clearance. However, infant blood
levels obtained were considered lethal.
In a retrospective cohort study of over 7,800 nursing women who used codeine after
birth, Juurlink et al. (2012) found that there were no more adverse events, hospitalizations, or
injuries when compared to a matched control group of women who did not use codeine after
birth.
Lam et al (2012) studied CNS depression in infants of mothers who used codeine,
oxycodone, or Tylenol. Infants of mothers who used oxycodone or codeine were much more
likely to have CNS depression, 21% and 16% of participants respectively, in comparison to
infants of mothers using Tylenol (0.5% of participants).

BREASTFEEDING AFTER MATERNAL ANESTHESIA

20

In 2020, Zipursky and Juurlink published a review article arguing the implausibility of the
Toronto case due to the small volume of opioids passed in the breastmilk, the need for severely
impaired kidney function to allow morphine accumulation, and the elevated level of codeine in
the postmortem analysis. Zipursky and Juurlink argued that the use of short-term codeine
should not be considered hazardous (2020). After the release of these results, the Canadian
Pharmacists Journal and the Canadian Family Physician printed a joint statement of retraction
for the original article that described the Toronto case. (Tsuyuki & Pimlott, 2020).
Due to the invariability of neonatal response to maternal codeine consumption, the
anesthetist should avoid codeine use in the lactating woman, instead using acetaminophen or
nonsteroidal anti-inflammatory drugs, shown to be as equally effective as codeine in the
treatment of postoperative pain (Choi et al., 2021). In the event that codeine use is initiated in
the lactating patient, Kelly et al. (2013), found a decrease in adverse neonatal effects after
implementing a breastfeeding guideline. This guideline advises codeine use no longer than four
days and to seek medical attention for neonatal or maternal CNS depression.
Hydromorphone (Dilaudid).
Hydromorphone is a longer acting opioid analgesic commonly used for perioperative
and postoperative pain control. Hydromorphone has low protein binding and moderate oral
bioavailability. The review of the literature resulted in one nonexperimental study describing
the use of intranasal hydromorphone in lactating mothers. Edwards et al. (2003) administered 2
mg of intranasal hydromorphone to eight lactating mothers between the ages of 24-32 years.
Plasma and milk samples were obtained from the participants at 2, 4, 6, 8, 12, and 24 hours
after hydromorphone administration. The calculated average relative infant dose of
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hydromorphone was 0.67%. The authors concluded that the risk for adverse effects for the
infant of a lactating mother receiving intranasal hydromorphone were low because of negligible
drug crossover into the breastmilk. Because intravenous and intranasal hydromorphone have
different bioavailabilities, 100% or 55%, these recommendations should not be generalized for
IV hydromorphone (Coda et al., 2003). Until more evidence is developed that determines the
safety of IV hydromorphone in lactating women, anesthetists should opt to use an alternative
agent.
Tramadol (Ultram).
Tramadol is a longer acting weak opioid analgesic that also inhibits norepinephrine and
serotonin reuptake. Tramadol is low protein binding and high oral bioavailability. Like codeine,
tramadol is a prodrug metabolized by the enzyme CYP2D6. Tramadol’s active metabolite, Odesmethyltramadol (M1), has a higher affinity for the opioid receptor than tramadol and is
responsible for the drug’s analgesic properties (WHO, 2018b).
This literature review resulted in two articles regarding the use of tramadol in
breastfeeding mothers. Both Ilett et al. (2008) and Salman et al. (2011) used the same dataset,
75 lactating women who received 50-100 mg of IV tramadol every four to six hours for
postoperative analgesia after cesarean section. Breastmilk and plasma samples were obtained
after 4 doses of medication, so as both tramadol and M1 would be at steady state
concentrations. Ilett et al. (2008) found that the relative infant dose of tramadol was 2.24% and
the relative infant dose of M1 was 0.64%, leading to a combined relative infant dose of 2.88%.
Salman et al. (2011) developed a pharmacokinetic model to estimate the relative infant dose
for infants of ultra-slow and ultra-fast maternal metabolizers. The authors found that the
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infants of ultra-slow metabolizers received an average relative dose of 3.07% and the infants of
ultra-fast metabolizers received an average relative dose of 3.09%. Although IV tramadol
appears to be safe in the participants in the above study, caution still should be exercised in the
administration of this medication due to the action of its metabolites.
Benzodiazepines.
Diazepam, lorazepam, and midazolam are GABA-A receptor agonists that increase the
binding affinity of the GABA-A receptor. Benzodiazepines are used in the perioperative period
for their sedative, anxiolytic, and amnestic properties.
Diazepam (Valium).
Diazepam is a long-acting benzodiazepine with extremely high protein binding, high lipid
solubility, high oral bioavailability, and an active metabolite, nordiazepam. The literature review
resulted in four articles describing the safety of diazepam in the nursing mother. Gilder et al.
(2021) administered low dose, less than 1 mg/10 kg, and high dose, greater than 1 mg/10 kg, of
IV diazepam to participants presenting for a postpartum tubal ligation. As the dose of diazepam
increased, infants of nursing mothers were more likely to result in hyperbilirubinemia and
weight loss. In a study by Borgatta et al. (1997), 9 participants received between 0-10 mg of IV
diazepam before a general anesthetic for tubal ligation. Participant’s breastmilk was obtained
three times within 24 hours after surgery. Diazepam and nordiazepam levels did not exceed the
lower limit of reportable range at all three sampling periods. Dusci et al. (1990) measured levels
of diazepam and metabolites in the plasma and breast milk of a woman who was on a taper
withdrawing from chronic benzodiazepine use. Diazepam and metabolite levels were also
measured in her one-year-old infant. The highest milk concentration of diazepam or
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metabolites found was 300 mcg/L of diazepam. Diazepam was undetectable in the infant
plasma, but low levels of metabolites were found. In addition, the infant did not present with
any signs of benzodiazepine intoxication. Erkkola and Kanto (1972) sampled the maternal
plasma, breastmilk, and infant plasma after mothers received 10 mg of diazepam three times a
day for six days. The highest infant plasma concentrations found were 172 ng/mL of diazepam
and 283 ng/mL of nordiazepam during day four of the study. Due to the high level of diazepam
and nordiazepam found in the infant plasma, the authors concluded that lactating mothers
should not take diazepam. Because of these results, diazepam’s pharmocokinetic
characteristics, and the decreased ability of infants to breakdown active metabolites, diazepam
should be avoided in the nursing mother until more consistent results are found.
Midazolam (Versed).
Midazolam is a short acting benzodiazepine with high protein binding, moderate oral
bioavailability, and water solubility. Midazolam breaks down into hydroxymidazolam, an active
metabolite with 10% of the potency of midazolam (Stoelting, 2015). This literature review
resulted in three articles describing midazolam use in the lactating mother. In a case study by
Koitabashi et al. (1997), a 20-year-old postpartum mother presented for a general anesthetic
for laparoscopic cholecystectomy with 6 mg of IV midazolam used for induction. Plasma and
breastmilk levels were obtained 1, 2, 4, 6, and 24 hours after administration. The highest
concentration, 9 ng/mL, was found one hour after administration. Nitsun et al. (2006)
administered 2 mg of IV midazolam to five lactating woman who presented for surgery.
Breastmilk was collected for 24 hours after surgery; the highest amount of midazolam collected
in the breastmilk was 0.08 mcg, or less than 1% of the relative infant dose. Matheson et al.
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(1990) studied the use of 15 mg of oral midazolam in 12 postpartum breastfeeding mothers.
Breastmilk concentrations were obtained 7 hours after administration. The average
concentration of midazolam was 3.3 ng/mL and the average concentration of
hydroxymidazolam was 3.4 ng/mL. Because of midazolam’s pharmacokinetics and extremely
low breastmilk concentrations in the above studies, IV and oral midazolam have a low
likelihood of causing adverse effects in the nursing infant.
Lorazepam (Ativan).
Lorazepam is a moderate acting benzodiazepine with high protein binding, high oral
bioavailability, low lipid solubility, and inactive metabolites. The literature review resulted in
three studies researching the safety of lorazepam in the lactating woman. Summerfield and
Nielsen (1985) administered 3.5 mg of oral lorazepam to lactating women presenting for
surgery. Four hours after administration, mean breastmilk levels of lorazepam were 8.5 ng/mL,
around 21% of mean plasma levels. A participant of a larger study by Whitelaw et al. (1981)
received 2.5 mg of lorazepam twice a day for five days after birth. On day five, her breastmilk
contained 12 ng/mL of lorazepam. Because of lorazepam lack of active metabolite and minimal
excretion into breastmilk, the likelihood of adverse events in the nursing infant are low.
Non-opioid analgesics.
Ketorolac (Toradol).
Ketorolac is a commonly used non-steroidal anti-inflammatory drug (NSAID) that is
commonly used in mothers in the postpartum period. Ketorolac has high protein binding and
oral bioavailability. The literature review resulted in one article describing the use of oral
Toradol in lactating mothers. Wischnik et al. (1989) administered 10 mg of oral Toradol four
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times a day for three days to postpartum women who were abstaining from breastfeeding.
Breastmilk and plasma samples were obtained every day during the intervention. The highest
ketorolac concentration detected in breastmilk was 7.9 ng/mL with a M:P ratio of 0.037. The
minimum amount of ketorolac excreted into breastmilk in this study indicates that nursing
infants of mothers who take Toradol are unlikely to suffer from any adverse effects.
Acetaminophen (Tylenol).
Acetaminophen is one of the most common medications advised for use in lactating
mothers. Tylenol is an antipyretic analgesic that has low protein binding, is lipid soluble, and is
mostly unionized at physiologic pH. The literature review resulted in three articles describing
the use of acetaminophen in lactating women. Berlin et al. (1980) administered one dose of 650
mg of oral Tylenol to 12 nursing mothers. Plasma and breastmilk concentrations were obtained
at 0, 0.25, 0.5, 0.75, 1, 2, 3, 5, 8, 12, and 24 hours after maternal dosing. The peak
concentration of Tylenol in breastmilk was 15 mcg/mL, found between 1-2 hours after dose
administration. Bitzen et al. (1981) administered one dose of 500 mg of oral Tylenol to
postpartum women who were abstaining from breastfeeding. Plasma and breastmilk levels of
Tylenol were obtained every 2, 4, 6, 8, 10, and 12 hours after administration. The highest
breastmilk concentration of Tylenol, 4.4 mcg/mL, was found 2 hours after administration.
Notarianni et al. (1987) administered 1 gram of acetaminophen to 4 nursing women. Plasma
and breastmilk Tylenol concentrations were obtained every 30 minutes for 3.5 hours. The
average peak Tylenol concentration in breastmilk was 10.1 mcg/mL. The average Tylenol
concentration in breastmilk was 6.1 mcg/mL. Because the amount of acetaminophen that
neonates would consume is negligible in comparison to an appropriate infant dose of Tylenol,
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maternal use of acetaminophen while nursing is highly unlikely to cause adverse effects in the
neonate.
Theoretical Framework
The Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) Model was utilized for this
scholarly project. The JHNEBP Model uses a 19-step process that is based on inquiry, practice,
and learning (Dang & Dearholt, 2018). The JHNEBP includes various tools that guide the
literature review, evidence synthesis, guideline development, and implementation plan for this
scholarly project. This author obtained permission from the Johns Hopkins Nursing Center for
Evidence-Based Practice to use the JHNEBP model and tools (Appendix C).
Clinical inquiry was the trigger for this process. Throughout the literature a need for a
postoperative breastfeeding protocol was indicated, as many anesthesia providers gave
incorrect postoperative recommendations to breastfeeding mothers (Moore et al., 2021; Reith
et al., 2018). This clinical inquiry began the PET process, which was divided into three phases:
practice question, evidence, and translation. The use of the PET process helps to develop best
practices and practice improvements. This JHNEBP model is a dynamic process that promotes
both learning and practice improvement, where new questions that arise trigger a new EBP
cycle (Melnyk & Fineout-Overholt, 2019). The JHNEBP model can be found in figure 1.
Figure 1
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Johns Hopkins Nurse Evidence-Based Practice Model.

(Dang and Dearholt, 2018)

The first phase of the PET process, practice question, included recruiting an
interprofessional team, developing and defining the scope of the EBP question, identifying
stakeholders, determining responsibility for project leadership, and scheduling team meetings
(Dang & Dearholt, 2018). The interprofessional team comprised of this graduate student and a
nurse anesthesia program director. The EBP question was as follows: In anesthesia providers
who provide care to lactating mothers (P), how does using an established postoperative
breastfeeding guideline (I) in comparison to current practice (C) affect provider knowledge and
confidence in providing postoperative breastfeeding recommendations (O)? The key
stakeholders include the anesthesia providers, anesthesia management, and patients at the
proposed facility of implementation. This graduate student was the primary investigator for this
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project. Their responsibilities included performing the literature review, developing the
postoperative breastfeeding guidelines, and developing a proposed implementation and
statistical analysis plan. The nurse anesthesia program director served as an advisor to the
graduate student. Meetings between the graduate student and the nurse anesthesia program
director occurred at least once a semester until project completion.
The next phase of the PET process, evidence, included an external evidence search,
appraisal of evidence, synthesis of evidence, and recommendation development based on
evidence synthesis (Dang & Dearholt, 2018). The graduate student performed a systematic
literature review of each commonly used anesthetic medication and “anesthesia” in multiple
research databases. The Research Evidence Appraisal Tool and the Non-research Evidence
Appraisal Tool, question-based guides that aid the reader in determining the strength of the
evidence gathered in the literature review, were used (Dang & Dearholt, 2018). The five levels
of evidence (I-V) in these tools were determined by research design. Evidence also received a
quality rating of good (A), fair (B), or poor (C), which was determined by the validity and
reliability of study methods (Dang & Dearholt, 2018). After the evidence was appraised and
selected, the Individual Evidence Summary Tool was used. This chart provided summary of each
source used for evidence synthesis. Information on this chart included the year of publication,
level of evidence, quality of evidence, and study findings (Dang & Dearholt, 2018). The
Synthesis Process and Recommendation Tool was used to compile the evidence gathered from
individual resources to answer the initial practice question. Findings were categorized by
evidence level. The Synthesis Process and Recommendation Tool also emphasizes the
importance of practice change that is compatible with organizational culture, practices, and

BREASTFEEDING AFTER MATERNAL ANESTHESIA

29

funding (Dang & Dearholt, 2018). This tool was used to summarize information from the
literature review and to develop the clinical guideline.
Lastly, the translation phase included creating a proposed guideline implementation and
assessment plan. The Action Planning Tool was utilized to develop a proposed plan for the
clinical implementation of the breastfeeding after anesthesia guideline. This tool aided the
project team in identifying milestones, barriers, and tasks needed for successful
implementation. The Action Planning Tool also required the identification of pre-intervention
and post-intervention measures.
Breastfeeding After Maternal Anesthesia Guideline
The following guideline is designed for use by anesthesia providers in the perioperative
period. Prolonged or excessive administration of these medications may alter their safety
profile. The guideline was developed to present implications of commonly used medications in
anesthesia on breastfeeding using a stop light appearance. Green indicates medications that
have little risk to the nursing infant. Yellow indicates medications that require vigilant
supervision, but benefits may outweigh the risks of medication use. Red indicates medications
that should be avoided in the nursing mother. Purple indicates medication with little human
research to affirm its use for lactating women, so avoidance is advised until further data is
developed. The developed guideline can be found in table 1.
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Table 1
Guideline for Administering Perioperative Medications to Lactating Women
Drug
Sedatives/Hypnotics
Propofol
Etomidate
Ketamine
Dexmedetomidine
Opioids
Fentanyl
Morphine
Meperidine
Codeine
Hydromorphone
Tramadol
Benzodiazepines
Diazepam
Midazolam
Lorazepam
Non-Opioid Analgesics
Ketorolac
Acetaminophen

Review
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
With Caution
Avoid
Insufficent Data Avoid
With Caution
With Caution
Low risk
Low risk
Low risk
Low risk

Comprehensive Plan
Setting
The setting of proposed project implementation will be a large urban hospital with an
active labor and delivery unit in the Midwest United States. The population for this scholarly
project will comprise of anesthesia providers at the facility of implementation. All anesthesia
providers will be included in the breastfeeding after anesthesia education and will receive the
breastfeeding after anesthesia guideline. Anesthesia providers at the hospital used for this
project will include anesthesiologists and CRNAs.
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Methods
Design.
The chief CRNA will use the PET Management Guide and the Action Planning Tool from
the JHNEBP model to establish the project timeline and plan of implementation with the
lactation specialist at the proposed facility of implementation. The chief CRNA and lactation
specialist for the facility of implementation will recruit an interprofessional team, identify
stakeholders, and schedule team meetings. Next, the team will obtain IRB approval. The chief
CRNA will draft an educational email with the postoperative breastfeeding guidelines and print
off the laminated QR codes that provide an electronic link to the guideline at this time.
Implementation.
The chief CRNA will email the pre-implementation survey to anesthesia providers. Two
weeks later, the guideline will be emailed to all anesthesia providers and the QR codes will be
affixed to dedicated areas. Post implementation data will be collected one month and six
months after implementation by email surveys. Data analysis will occur after the six-month
post-implementation data is collected.
Integration into Practice.
To continue anesthesia provider knowledge and confidence in providing postoperative
breastfeeding recommendations, the guideline will be updated yearly by the hospital lactation
specialist and chief CRNA with new evidence and given to anesthesia providers.
Timeline and Budget
Timeline.
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The duration estimate for the proposed implementation of postoperative breastfeeding
guideline is eleven months.
-Month One: Establish timeline and plan of implementation with chief CRNA and lactation
specialist. Submit and obtain IRB approval or exemption. Print off guidelines and QR codes.
-Month Two: Send pre-implementation survey.
-Month Three: Guideline emailed to staff and QR codes affixed to dedicated areas.
-Month Four: Collect one month post implementation data.
-Month Nine: Post implementation data collected six months after implementation.
-Month Ten: Data analysis and final report.
-Month Eleven: Poster presentation.
Budget.
The budget expectations for this proposed guideline implementation are minimal. The
chief CRNA and the lactation specialist will be salaried through the proposed hospital of
implementation, and no other compensation will occur. Distribution of the guideline will occur
electronically by facility email. The participants of the multidisciplinary team will be recruited
on a volunteer basis and will be uncompensated for their time. A laminated QR code that leads
to the postoperative breastfeeding guidelines and additional information will be fixed to each
Pyxis machine in the pre-operative, intraoperative, post-operative, labor and delivery, and postpartum units. The cost of 50 QR codes will be about $100. To encourage anesthesia providers to
complete surveys to obtain project data, all participants will be entered into a raffle for one $50
gift card. Lastly, at the conclusion of the project, a poster will be printed for presentation. This
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cost of printing will be between $50-$100. Overall, the maximum estimated budget for this
scholarly project will be between $200-$250.
Outcome Analysis Plan
Data Collection.
Anesthesia providers at the proposed facility of implementation will complete a tenquestion assessment about breastfeeding after anesthesia. Providers will also rate their
confidence in providing recommendations regarding breastfeeding in the perioperative period.
Data collection will occur three times: before guideline implementation, one month after
guideline implementation to assess for initial knowledge and confidence change, and six
months after guideline implementation to assess for knowledge and confidence retention. All
data collection will occur by electronic correspondence.
Data Analysis.
Knowledge and confidence data collected from pre-implementation, one month after
implementation, and six months after implementation will be compared using the one-way
analysis of variance (ANOVA) test. Knowledge questions answered will be scored as “correct” or
“incorrect”. The knowledge assessment will be scored from one to ten. Provider confidence
questions will be answered on a five-point Likert scale, where one is “not confident at all” and
five is “completely confident”. The knowledge and confidence assessment can be found in
Appendix D.
Facilitators
At the proposed institution of implementation, the chief CRNA and a lactation
consultant will serve on the multidisciplinary team to guide facility specific implementation.
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Anesthesia providers including CRNAs and anesthesiologists at the institution of
implementation will be the final facilitators of this guideline.
Project Evaluation
The success of this scholarly project will be based on meeting the objectives established
using the PET management guide, maintaining the project timeline, and a statistically significant
increase in knowledge and confidence in providers regarding breastfeeding in the perioperative
setting.
Conclusion
The purpose of the scholarly project was to develop a set of evidenced-based practice
guideline recommendations and a proposed implementation plan for anesthesia providers to
use in support of breastfeeding mothers who recover from surgery. Using these guidelines and
implementation plan, the CRNA can assess current provider knowledge regarding
breastfeeding, implement evidence-based postoperative breastfeeding guidelines, assess
effectiveness of the implementation, and ensure lasting change. Further investigation in the
safety of anesthetic medications in the lactating mother is warranted. Gaps in the literature
indicate the need for up to date and large cohort studies in the use of anesthetic medications in
all lactating mothers and additionally in lactating mothers of children with comorbid disease.
Limitations and Barriers
Literature regarding breastfeeding safety for some medications used in the
perioperative area is limited (Oliveira et al., 2018; Verstegen & Ito, 2019; Cobb et al., 2015). In
addition, some lactation safety references may be older than ten years. If high quality evidence
was unable to be found, LactMed, an online drug and lactation database, was utilized (LactMed,
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n.d.). Though limited, there are some anticipated barriers to the implementation of this
scholarly project. Provider hesitancy to adopt new guidelines may also occur (Alatawi et al.,
2020). Lastly, provider knowledge and confidence may decrease after implementation, as
improvements can be difficult to sustain without further intervention.

35

BREASTFEEDING AFTER MATERNAL ANESTHESIA

36

References
AANA. (n.d.). Does Anesthesia Affect a New Mom's Ability to Breastfeed? Aana.com. Retrieved
March 1, 2022, from https://www.aana.com/patients/does-anesthesia-affect-a-newmom-s-ability-to-breastfeed
Alatawi, M., Aljuhani, E., Alsufiany, F., Aleid, K., Rawah, R., Aljanabi, S., & Banakhar, M. (2020).
Barriers of implementing evidence-based practice in Nursing Profession: A literature
review. American Journal of Nursing Science, 9(1), 35.
https://doi.org/10.11648/j.ajns.20200901.16
Al-Tamimi, Y., Ilett, K. F., Paech, M. J., O’Halloran, S. J., & Hartmann, P. E. (2011). Estimation of
infant dose and exposure to pethidine and norpethidine via breast milk following patientcontrolled epidural pethidine for analgesia post caesarean delivery. International Journal
of Obstetric Anesthesia, 20(2), 128–134. https://doi.org/10.1016/j.ijoa.2010.12.004
American Academy of Pediatrics (AAP). (2012). Breastfeeding and the use of human
milk. Pediatrics, 129(3), e827–e841. Retrieved
from https://pediatrics.aappublications.org/content/129/3/e827
ASA. (2019). Statement on Resuming Breastfeeding after Anesthesia. Statement on Resuming
Breastfeeding after Anesthesia | American Society of Anesthesiologists (ASA).
https://www.asahq.org/standards-and-guidelines/statement-on-resuming-breastfeedingafter-anesthesia.

BREASTFEEDING AFTER MATERNAL ANESTHESIA

37

Baka, N.-E., Bayoumeu, F., Boutroy, M.-J., & Laxenaire, M.-C. (2002). Colostrum morphine
concentrations during Postcesarean intravenous patient-controlled analgesia. Anesthesia
& Analgesia, 94(1), 184–187. https://doi.org/10.1213/00000539-200201000-00035
Berlin, C. M., Jr, Yaffe, S. J., & Ragni, M. (1980). Disposition of acetaminophen in milk, saliva,
and plasma of lactating women. Pediatric pharmacology (New York, N.Y.), 1(2), 135–141.
Bitzen, P.O., Gustafsson, B., Jostell, K. G., Melander, A., & Wahlin-Boll, E. (1981). Excretion of
paracetamol in human breast milk. European Journal of Clinical Pharmacology, 20(2),
123–125. https://doi.org/10.1007/bf00607148
Butwick, A. J., Wong, C. A., & Guo, N. (2018). Maternal Body Mass Index and Use of Labor
Neuraxial Analgesia. Anesthesiology, 129(3), 448–458.
https://doi.org/10.1097/aln.0000000000002322
Centers for Disease Control and Prevention (CDC). (2021). Facts. Centers for Disease Control
and Prevention. Retrieved from https://www.cdc.gov/breastfeeding/data/facts.html
Choi, M., Wang, L., Coroneos, C. J., Voineskos, S. H., & Paul, J. (2021). Managing postoperative
pain in adult outpatients: A systematic review and meta-analysis comparing codeine
with NSAIDs. Canadian Medical Association Journal, 193(24).
https://doi.org/10.1503/cmaj.201915
Cobb, B., Liu, R., Valentine, E., & Onyi, O. (2015). Breastfeeding after Anesthesia: A Review for
Anesthesia Providers Regarding the Transfer of Medications into Breast Milk.

BREASTFEEDING AFTER MATERNAL ANESTHESIA

38

Translational Perioperative and Pain Medicine, 2(2). https://doi.org/10.31480/23304871/023
Coda, B. A., Rudy, A. C., Archer, S. M., & Wermeling, D. P. (2003). Pharmacokinetics and
bioavailability of single-dose intranasal hydromorphone hydrochloride in Healthy
Volunteers. Anesthesia & Analgesia, 117–123.
https://doi.org/10.1213/01.ane.0000066311.40978.4f
Clements, J., Nimmo, W., Grant, I. (1982). Bioavailability, pharmacokinetics, and analgesic
activity of ketamine in humans. J Pharm Sci 71(5):539–542
Dalal, P. G., Bosak, J., & Berlin, C. (2014). Safety of the breast-feeding infant after maternal
anesthesia. Pediatric Anesthesia, 24(4), 359–371. https://doi.org/10.1111/pan.12331
Dang, D., & Dearholt, S. (2018). Johns Hopkins nursing evidence-based practice: Model and
guidelines. Sigma Theta Tau International.
Dailland, P., Cockshott, I. D., Lirzin, J. D., Jacquinot, P., Jorrot, J. C., Devery, J., Harmey, J. L., &
Conseiller, C. (1989). Intravenous propofol during cesarean section. Obstetric Anesthesia
Digest, 10(2), 84. https://doi.org/10.1097/00132582-199007000-00035
Dodd, S. E., Hunter Guevara, L. R., Datta, P., Rewers-Felkins, K., Baker, T., & Hale, T. W. (2021).
Dexmedetomidine levels in breast milk: Analysis of breast milk expressed during and after
awake craniotomy. Breastfeeding Medicine, 16(11), 919–921.
https://doi.org/10.1089/bfm.2021.0138

BREASTFEEDING AFTER MATERNAL ANESTHESIA

39

Edwards, J. E., Rudy, A. C., Wermeling, D. P., Desai, N., & McNamara, P. J. (2003).
Hydromorphone transfer into breast milk after intranasal administration.
Pharmacotherapy, 23(2), 153–158. https://doi.org/10.1592/phco.23.2.153.32081
Erkkola, R., & Kanto, J. (1972). Diazepam and breast-feeding. The Lancet, 299(7762), 1235–
1236. https://doi.org/10.1016/s0140-6736(72)90954-3
Esener, Z., Sarihasan, B., Güven, H., & Ustün, E. (1992). Thiopentone and etomidate
concentrations in maternal and umbilical plasma, and in colostrum. British journal of
anaesthesia, 69(6), 586–588. https://doi.org/10.1093/bja/69.6.586
Folh, K., & Stephens, K. (2019). Implementation of a Post-Anesthesia Care Breastfeeding
Program. Journal of Obstetric, Gynecologic & Neonatal Nursing, 48(3).
https://doi.org/10.1016/j.jogn.2019.04.015
Gilder, M. E., Tun, N. W., Carter, A., Tan, F. F., Min, A. M., Eh, H., Aye, P., Carrara, V. I.,
Angkurawaranon, C., & McGready, R. (2021). Outcomes for 298 breastfed neonates
whose mothers received ketamine and diazepam for postpartum tubal ligation in a
resource-limited setting. BMC Pregnancy and Childbirth, 21(1).
https://doi.org/10.1186/s12884-021-03610-1
Goma, H. M., Said, R. N., & El-Ela, A. M. (2008). Study of the newborn feeding behaviors and
fentanyl concentration in colostrum after an analgesic dose of epidural and intravenous
fentanyl in cesarean section. Saudi medical journal, 29(5), 678–682.

BREASTFEEDING AFTER MATERNAL ANESTHESIA

40

Gilder, M. E., Tun, N. W., Carter, A., Tan, F. F., Min, A. M., Eh, H., … McGready, R. (2021).
Outcomes for 298 breastfed neonates whose mothers received ketamine and diazepam
for postpartum tubal ligation in a resource-limited setting. BMC Pregnancy and
Childbirth, 21(1). https://doi.org/10.1186/s12884-021-03610-1
Ilett, K. F., Paech, M. J., Page-Sharp, M., Sy, S. K., Kristensen, J. H., Goy, R., Chua, S., Christmas,
T., & Scott, K. L. (2008). Use of a sparse sampling study design to assess transfer of
Tramadol and its O-desmethyl metabolite into transitional breast milk. British Journal of
Clinical Pharmacology, 65(5), 661–666. https://doi.org/10.1111/j.13652125.2008.03117.x
Juurlink, D. N., Gomes, T., Guttmann, A., Hellings, C., Sivilotti, M. L., Harvey, M.-A., & Mamdani,
M. M. (2012). Postpartum maternal codeine therapy and the risk of adverse neonatal
outcomes: A retrospective cohort study. Clinical Toxicology, 50(5), 390–395.
https://doi.org/10.3109/15563650.2012.681052
Kelly, L. E., Chaudhry, S. A., Rieder, M. J., ‘t Jong, G., Moretti, M. E., Lausman, A., Ross, C.,
Berger, H., Carleton, B., Hayden, M. R., Madadi, P., & Koren, G. (2013). A clinical tool for
reducing central nervous system depression among neonates exposed to codeine
through breast milk. PLoS ONE, 8(7). https://doi.org/10.1371/journal.pone.0070073
Koitabashi, T., Satoh, N., & Takino, Y. (1997). Intravenous midazolam passage into breast milk.
Journal of Anesthesia, 11(3). https://doi.org/10.1007/s0054070110242
LactMed. (2018). Drugs and lactation database. National Library of Medicine.

BREASTFEEDING AFTER MATERNAL ANESTHESIA

41

Lam, J., Kelly, L., Ciszkowski, C., Landsmeer, M. L. A., Nauta, M., Carleton, B. C., Hayden, M. R.,
Madadi, P., & Koren, G. (2012). Central Nervous System Depression of neonates breastfed
by mothers receiving oxycodone for postpartum analgesia. The Journal of Pediatrics,
160(1). https://doi.org/10.1016/j.jpeds.2011.06.050
Lobkova, N., & Wolf, E. W. (2014). Performing Elective Surgery on the Breastfeeding Patient.
Foot & Ankle Specialist, 7(3), 225–230. https://doi.org/10.1177/1938640014532132
Madadi, P., Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., Leeder, J. S., Teitelbaum, R., Karaskov,
T., & Aleksa, K. (2007). Safety of codeine during breastfeeding: fatal morphine poisoning
in the breastfed neonate of a mother prescribed codeine. Canadian Family Physician
Medecin de Famille Canadien, 53(1), 33–35.
Madadi, P., Ross, C. J. D., Hayden, M. R., Carleton, B. C., Gaedigk, A., Leeder, J. S., & Koren, G.
(2008). Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine
during breastfeeding: A case–control study. Clinical Pharmacology & Therapeutics, 85(1),
31–35. https://doi.org/10.1038/clpt.2008.157
Martin, E., Vickers, B., Landau, R., & Reece-Stremtan, S. (2018). ABM Clinical Protocol #28,
Peripartum Analgesia and Anesthesia for the Breastfeeding Mother. Breastfeeding
Medicine, 13(3), 164–171. https://doi.org/10.1089/bfm.2018.29087.ejm

BREASTFEEDING AFTER MATERNAL ANESTHESIA

42

Matheson, I., Lunde, P. K., & Bredesen, J. E. (1990). Midazolam and nitrazepam in the Maternity
Ward: Milk concentrations and clinical effects. British Journal of Clinical Pharmacology,
30(6), 787–793. https://doi.org/10.1111/j.1365-2125.1990.tb05443.x
Melnyk, B. M., & Fineout-Overholt, E. (2019). Evidence-based practice in Nursing & Healthcare:
A guide to best practice. Wolters Kluwer.
Mitchell, J., Jones, W., Winkley, E., & Kinsella, S. M. (2020). Guideline on anaesthesia and
sedation in breastfeeding women 2020. Anaesthesia, 75(11), 1482–1493.
https://doi.org/10.1111/anae.15179
Moore, C. B., Bond, J. D., Bundoc, E. G., Hefley, J. B., Wofford, K. A., & Bonds, R. L. (2021).
Resuming Breastfeeding After Surgery: Influencing Practice Recommendations. Journal
of PeriAnesthesia Nursing. https://doi.org/10.1016/j.jopan.2020.12.010
Nakanishi, R., Yoshimura, M., Suno, M., Yamamoto, K., Ito, H., Uchimine, Y., Toriumi, T.,
Kurosawa, A., Sugawara, A., & Kunisawa, T. (2017). Detection of dexmedetomidine in
human breast milk using liquid chromatography–tandem mass spectrometry:
Application to a study of drug safety in breastfeeding after cesarean section. Journal of
Chromatography B, 1040, 208–213. https://doi.org/10.1016/j.jchromb.2016.11.015
Nitsun, M., Szokol, J., Saleh, H., Murphy, G., Vender, J., Luong, L., Raikoff, K., & Avram, M.
(2006). Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast
milk. Clinical Pharmacology & Therapeutics, 79(6), 549–557.
https://doi.org/10.1016/j.clpt.2006.02.010

BREASTFEEDING AFTER MATERNAL ANESTHESIA

43

Notarianni, L. J., Oldham, H. G., & Bennett, P. N. (1987). Passage of paracetamol into breast milk
and its subsequent metabolism by the neonate. British journal of clinical pharmacology,
24(1), 63–67. https://doi.org/10.1111/j.1365-2125.1987.tb03137.x
Oliveira, M. R., Santos, M. G., Aude, D. A., Lima, R. M., Módolo, N. S., & Navarro, L. H. (2019).
Should maternal anesthesia delay breastfeeding? A systematic review of the literature.
Brazilian Journal of Anesthesiology (English Edition), 69(2), 184–196.
https://doi.org/10.1016/j.bjane.2018.12.006
Ramsay, M. A., & Luterman, D. L. (2004). Dexmedetomidine as a total intravenous anesthetic
agent. Anesthesiology, 101(3), 787–790. https://doi.org/10.1097/00000542-20040900000028
Reece-Stremtan, S., Campos, M., Kokajko, L., Brodribb, W., Noble, L., Brent, N., Bunik, M.,
Harrel, C., Lawrence, R. A., LeFort, Y., Marinelli, K. A., Rosen-Carole, C., Rothenberg, S.,
Seo, T., St. Fleur, R., & Young, M. (2017). ABM Clinical Protocol #15: Analgesia and
Anesthesia for the Breastfeeding Mother, Revised 2017. Breastfeeding Medicine, 12(9),
500–506. https://doi.org/10.1089/bfm.2017.29054.srt
Reith, E. F., Barnett, K. M., & Simon, J. A. (2018). Implementation and Organization of a
Perioperative Lactation Program: A Descriptive Study. Breastfeeding Medicine, 13(2), 97–
105. https://doi.org/10.1089/bfm.2017.0193

BREASTFEEDING AFTER MATERNAL ANESTHESIA

44

Ring, L., Landau, R., & Delgado, C. (2021). The Current Role of General Anesthesia for Cesarean
Delivery. Current Anesthesiology Reports, 11(1), 18–27. https://doi.org/10.1007/s40140021-00437-6
Salman, S., Sy, S. K., Ilett, K. F., Page-Sharp, M., & Paech, M. J. (2011). Population
pharmacokinetic modeling of Tramadol and its O-desmethyl metabolite in plasma and
breast milk. European Journal of Clinical Pharmacology, 67(9), 899–908.
https://doi.org/10.1007/s00228-011-1023-6
Steer, P. L., Biddle, C. J., Marley, W. S., Lantz, R. K., & Sulik, P. L. (1992). Concentration of
fentanyl in colostrum after an analgesic dose. Canadian Journal of Anaesthesia, 39(3),
231–235. https://doi.org/10.1007/bf03008782
Stuttmann, R., Schäfer, C., Hilbert, P., Meyer, M. R., & Maurer, H. H. (2010). The breast feeding
mother and xenon anaesthesia: Four case reports. breast feeding and xenon
anaesthesia. BMC Anesthesiology, 10(1). https://doi.org/10.1186/1471-2253-10-1
Summerfield, R. J., & Nielsen, M. S. (1985). Excretion of Lorazepam into breast milk. British
Journal of Anaesthesia, 57(10), 1042–1043. https://doi.org/10.1093/bja/57.10.1042-a
Tsuyuki, R. T., & Pimlott, N. (2020). Risks of maternal codeine intake in breast-fed infants: A
joint statement of retraction from the Canadian Pharmacists Journal and Canadian
family physician. Canadian Pharmacists Journal / Revue Des Pharmaciens Du Canada,
154(1), 7–8. https://doi.org/10.1177/1715163520970443

BREASTFEEDING AFTER MATERNAL ANESTHESIA

45

Wallach, J., Brandt, S. D. (2018). 1,2-diarylethylamine- and ketamine-based new psychoactive
substances. New Psychoactive Substances, 305–352.
https://doi.org/10.1007/164_2018_148
Westerfield, K. L., Koenig, K., & Oh, R. C. (2018). Breastfeeding: Common Questions and
Answers. American Family Physician. https://www.aafp.org/afp/2018/0915/p368.html.
Whitelaw, A., Mcfadyen, I., & Cummings, A. (1981). Effect of maternal lorazepam on the
Neonate. BMJ, 282(6280), 1973–1974. https://doi.org/10.1136/bmj.282.6280.1973-c
Willmann, S., Edginton, A. N., Coboeken, K., Ahr, G., & Lippert, J. (2009). Risk to the breast-fed
neonate from codeine treatment to the mother: A quantitative mechanistic modeling
study. Clinical Pharmacology & Therapeutics, 86(6), 634–643.
https://doi.org/10.1038/clpt.2009.151
Wischnik, A., Manth, S. M., Lloyd, J., Bullingham, R., & Thompson, J. S. (1989). The excretion of
Ketorolac tromethamine into breast milk after multiple oral dosing. European Journal of
Clinical Pharmacology, 36(5), 521–524. https://doi.org/10.1007/bf00558080
Wittels, B., Scot, D. T., & Sinatra, R. S. (1990). Exogenous opioids in human breast milk and
acute neonatal neurobehavior. Anesthesiology, 73(5), 864–869.
https://doi.org/10.1097/00000542-199011000-00012
Wittels, B., Glosten, B., Faure, E. A., Moawad, A. H., Ismail, M., Hibbard, J., Senal, J. A., Cox, S.
M., Blackman, S. C., Karl, L., & Thisted, R. A. (1997). Postcesarean analgesia with both

BREASTFEEDING AFTER MATERNAL ANESTHESIA

46

epidural morphine and intravenous patient-controlled analgesia. Anesthesia &
Analgesia, 85(3), 600–606. https://doi.org/10.1097/00000539-199709000-00021
Wolfson, P., Cole, R., Lynch, K., Yun, C., Wallach, J., Andries, J., & Whippo, M. (2021). The
pharmacokinetics of ketamine in the breast milk of lactating women: Quantification of
ketamine and metabolites. https://doi.org/10.22541/au.161325028.80476344/v1
World Health Organization (WHO). (2018a). Breastfeeding. World Health Organization.
Retrieved from
https://apps.who.int/nutrition/topics/exclusive_breastfeeding/en/index.html
World Health Organization (WHO). (2018b). Critical review report: Tramadol - World Health
Organization. Critical Review Report: Tramadol . Retrieved March 7, 2022, from
https://www.who.int/medicines/access/controlled-substances/Tramadol.pdf?ua=1
Yoshimura, M., Kunisawa, T., Suno, M., Sugawara, A., Kurosawa, A., Nakanishi, R., Aoki, K., &
Toriumi, T. (2017). Intravenous dexmedetomidine for cesarean delivery and its
concentration in colostrum. International Journal of Obstetric Anesthesia, 32, 28–32.
https://doi.org/10.1016/j.ijoa.2017.05.002
Zipursky, J., & Juurlink, D. N. (2020). The implausibility of neonatal opioid toxicity from
breastfeeding. Clinical Pharmacology & Therapeutics, 108(5), 964–970.
https://doi.org/10.1002/cpt.1882

BREASTFEEDING AFTER MATERNAL ANESTHESIA

47
Appendix A

Citation

Conceptual Framework

(Author, Year, Title, etc...)

(Theoretical basis for
study)

Mitchell, J., Jones, W., Winkley, E., & Kinsella, S. M.
(2020). Guideline on anaesthesia and sedation in
breastfeeding Women 2020. Anaesthesia, 75(11),
1482–1493. https://doi.org/10.1111/anae.15179

Gilder, M. E., Tun, N. W., Carter, A., Tan, F. F., Min, A.
M., Eh, H., … McGready, R. (2021). Outcomes for 298
breastfed neonates whose mothers received
ketamine and diazepam for postpartum tubal ligation
in a resource-limited setting. BMC Pregnancy and
Childbirth, 21(1). https://doi.org/10.1186/s12884021-03610-1

Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
Performed literature
Clinical Guideline Used lactation
NA
review to provide
databases, current
evidence based
guidelines, and
information about the
breastfeeding
pharmacokinetics and
expert journals and
passage into breastmilk of
websites.
drugs commonly used in
anesthesia.

Identified adverse
Retrospective
neonatal outcomes
Cohort Study
associated with varying
levels of ketamine and
diazepam in breastfeeding
mothers.

298 breastfeeding
mothers who were
undergoing a tubal
ligation

Low Ketamine
Administration
(<1.16 mg/kg of
maternal body
weight)
High Ketamine
Administration (≥
1.16 mg kg of
maternal body
weight)
Low Diazepam
Administration (< 1
mg/10kg maternal
body weight)
High Diazepam
Administration (≥1
mg/10kg maternal
body weight)

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)
NA

NA

Level of Quality
evidence of
evidence

Almost all medications V
used in the
perioperative setting
do increase the risk of
harm to the infant.
Opioids have caused
respiratory depression
in infants, and their use
should be monitored
closely.
Clinically significant STATA-15
Weight loss and
III
weight loss
jaundice were
unaffected by the
Chi2 test
amount of maternal
Hyperbilirubinemia
ketamine received. As
Non-parametric tests doses of diazepam
Neurodevelopment of association
were increased, there
at 1 year
were increased risk of
Mann-Whitney Test weight loss and
jaundice.
Spears correlation
coefficient

A

A

BREASTFEEDING AFTER MATERNAL ANESTHESIA

Citation

Conceptual Framework

(Author, Year, Title, etc...)

(Theoretical basis for
study)

Design/ Method Sample/Setting

Cobb, B., Liu, R., Valentine, E., & Onyi, O. (2015).
Breastfeeding after Anesthesia: A Review for
Anesthesia Providers Regarding the Transfer of
Medications into Breast Milk. Translational
Perioperative and Pain Medicine, 2(2).
https://doi.org/10.31480/2330-4871/023

Review of the literature to Systematic
determine common
Review
anesthesia medications’
passage into breast milk
and implications for
breastfed infants.

Oliveira, M. R., Santos, M. G., Aude, D. A., Lima, R. M.,
Módolo, N. S., & Navarro, L. H. (2019). Should
maternal anesthesia delay breastfeeding? A
systematic review of the literature. Brazilian Journal
of Anesthesiology (English Edition), 69(2), 184–196.
https://doi.org/10.1016/j.bjane.2018.12.006

A systematic literature
review used to develop
recommendations
regarding breastfeeding
after anesthesia.

Dalal, P. G., Bosak, J., & Berlin, C. (2014). Safety of the
breast-feeding infant after maternal anesthesia.
Pediatric Anesthesia, 24(4), 359–371.
https://doi.org/10.1111/pan.12331

48

Systematic
Review

Reviewed the
Systematic
pharmacological
Review
implications for breastmilk
of common medications
used by anesthetists
ASA. (2019). Statement on Resuming Breastfeeding Clinical guideline
Clinical Guideline
after Anesthesia. Statement on Resuming
established by the
Breastfeeding after Anesthesia | American Society of American Society of
Anesthesiologists (ASA).
Anesthesiologists to
https://www.asahq.org/standards-andprovide anesthetists with
guidelines/statement-on-resuming-breastfeedinginformation regarding
after-anesthesia.
adverse neonatal effects
from maternal
anesthetics.

Major Variables;
definitions

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

NA

NA

NA

NA

NA

Searched available NA
literature in the
Pubmed database.

NA

NA

NA

NA

NA

Most medications used V
in typical anesthesia
practice are safe for
use in women who are
breastfeeding. Codeine
and meperidine should
be avoided, and
hydromorphone should
be used with caution in
this patient population.
The transfer of
V
medications to
breastmilk from single
dosages of medication
is very small and the
effects are negligible.
Large and repeated
doses of medications
increase the risk of
adverse effects in the
neonate. Diazepam and
meperidine should be
avoided in nursing
women.
The anesthetist should V
avoid using narcotics,
benzodiazepines, and
medications with active
metabolites.
Narcotics and
IV
medications with active
metabolites should be
avoided in nursing
mothers. Patients
should not be
encouraged to pump
and dump.

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
Reviewed
NA
medications used
for neuraxial,
general, and
regional anesthesia
to assess the affect
on neonatal
outcomes.

50 studies (16

Outcome
Measurement
(What scales used –
reliability
information – alphas)

reviews, 13
prospective trials,
4 retrospective
observational
studies, 6 case
reports, 9 RCTs, 1
case-control
study, and 1
website access)

NA

Level of Quality
evidence of
evidence

A

A

A

B

BREASTFEEDING AFTER MATERNAL ANESTHESIA

49

Citation

Conceptual Framework

Design/ Method Sample/Setting

(Author, Year, Title, etc...)

(Theoretical basis for
study)

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
Clinical Guideline NA
NA

Martin, E., Vickers, B., Landau, R., & Reece-Stremtan,
S. (2018). ABM Clinical Protocol #28, Peripartum
Analgesia and Anesthesia for the Breastfeeding
Mother. Breastfeeding Medicine, 13(3), 164–171.
https://doi.org/10.1089/bfm.2018.29087.ejm

Clinical protocol
developed by the
Association of
Breastfeeding Medicine to
direct anesthetic practice
for the peripartum
patient.

Lobkova, N., & Wolf, E. W. (2014). Performing Elective
Surgery on the Breastfeeding Patient. Foot & Ankle
Specialist, 7(3), 225–230.
https://doi.org/10.1177/1938640014532132

Reviewed the
Systematic
pharmacokinetic
Review
implications of anesthesia
in the mother- baby dyad.

NA

Reece-Stremtan, S., Campos, M., Kokajko, L.,
Brodribb, W., Noble, L., Brent, N., Bunik, M., Harrel,
C., Lawrence, R. A., LeFort, Y., Marinelli, K. A., RosenCarole, C., Rothenberg, S., Seo, T., St. Fleur, R., &
Young, M. (2017). ABM Clinical Protocol #15:
Analgesia and Anesthesia for the Breastfeeding
Mother, Revised 2017. Breastfeeding Medicine, 12(9),
500–506.
https://doi.org/10.1089/bfm.2017.29054.srt

Moore, C. B., Bond, J. D., Bundoc, E. G., Hefley, J. B.,
Wofford, K. A., & Bonds, R. L. (2021). Resuming
Breastfeeding After Surgery: Influencing Practice
Recommendations. Journal of PeriAnesthesia Nursing.
https://doi.org/10.1016/j.jopan.2020.12.010

Major Variables;
definitions

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)

Level of Quality
evidence of
evidence

NA

NA

IV

A

NA

NA

NA

A

Clinical protocol
Clinical Guideline NA
developed by the
Association of
Breastfeeding Medicine to
direct anesthetic practice
for the lactating patient
who presents for nonobstetric surgery.

NA

NA

NA

Provided an overview V
of the safety of
common medications
in anesthesia. It is
essential to reference a
reliable lactation
medication database
before administering
medications to
breastfeeding mothers.
Provides anesthesia
IV
recommendations for
lactating mothers
including common
medications used in
surgery and their
effects on the nursing
infant.

Reviewed the literature
Evidence Based
for best practice regarding Practice project
breastfeeding after
anesthesia. Used findings
to educate OR staff and
develop unit policy.

Provided education Change in practice Chi2 test
on breastfeeding habits
safety after
McNemar test
anesthesia.
Change in confidence
when making
Wilcoxon test
Developed
recommendations
departmental
Mann-Whitney Test
policy.
Change in knowledge

OR staff who received IV
training reported
increased confidence
when recommending
breastfeeding after
anesthesia, increased
knowledge, and an
increase in staff who
would recommend

B

OR staff at a midsized military
hospital
N=10

A

BREASTFEEDING AFTER MATERNAL ANESTHESIA

Citation

Conceptual Framework

(Author, Year, Title, etc...)

(Theoretical basis for
study)

50

Design/ Method Sample/Setting

Nitsun, M., Szokol, J., Saleh, H., Murphy, G., Vender,
J., Luong, L., Raikoff, K., & Avram, M. (2006).
Pharmacokinetics of midazolam, propofol, and
fentanyl transfer to human breast milk. Clinical
Pharmacology & Therapeutics, 79(6), 549–557.
https://doi.org/10.1016/j.clpt.2006.02.010

Collected and analyzed
Quasibreastmilk drug levels of experimental
women who received
study
midazolam, propofol, and
fentanyl for a general
anesthetic.

Stuttmann, R., Schäfer, C., Hilbert, P., Meyer, M. R., &
Maurer, H. H. (2010). The breast feeding mother and
xenon anaesthesia: Four case reports. breast feeding
and xenon anaesthesia. BMC Anesthesiology, 10(1).
https://doi.org/10.1186/1471-2253-10-1

Collected and analyzed
breastmilk drug levels of
women who received
propofol, remifentanil,
and inhaled xenon for a
general anesthetic.

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)

Five lactating
women who had
scheduled
procedures
requiring general
anesthesia.

Nonexperimental Four lactating
study
women who
presented for
urgent surgery on
the condition that
their ability to
breastfeed would
not be impaired.
Dailland, P., Cockshott, I. D., Lirzin, J. D., Jacquinot, P., Collected and analyzed
Nonexperimental 21 ASA status 1
Jorrot, J. C., Devery, J., Harmey, J. L., & Conseiller, C. colostrum and blood from study
patients 37-40
(1989). Intravenous propofol during cesarean section. mothers who required
weeks’ gestation,
Obstetric Anesthesia Digest, 10(2), 84.
general anesthesia for
however, colostrum
samples were only
https://doi.org/10.1097/00132582-199007000-00035 cesarean section.
collected from 7
patients.

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

Kruskal-Wallis test

breastfeeding after
anesthesia.

(What scales used –
reliability
information – alphas)

Level of Quality
evidence of
evidence

Administered 2 mg
of midazolam, 100
mcg of fentanyl,
and 2.5 mg/kg of
propofol for
induction of
general anesthesia.

Drug levels in blood The median volume The fraction of
III
were measured up to of breastmilk pumped maternal dose
7 hours after drug
over 24 hours was
transferred to
administration. All 250 mL. The median breastmilk for all drugs
breastmilk was
amount of drug in the was less than 0.001%
collected for 24
breast milk was 0.08 for all drugs.
hours after fentanyl mcg of midazolam, 26
administration and mcg of propofol, and
assessed for drug
0.024 mcg of fentanyl.
levels.
Used a propofol
Propofol levels in
The percentage of
The percentage of the III
bolus and infusion breastmilk were
drug in 150 mL of
maternal dose was
for induction and measured 90 and
breastmilk was
0.09% at 90 minutes
maintenance of
300 minutes after
calculated.
and 0.017%.
general anesthesia propofol
before beginning administration.
inhaled xenon.

B

Phase 1administered a 2.5
mg/kg dose of
propofol for
induction followed
by halothane and
nitrous for
maintenance of
anesthesia.

A

Phase 2administered a 2.5
mg/kg dose of
propofol for
induction followed
by a continuous

Propofol levels in
breastmilk were
assessed 4 and 8
hours after birth in
phase 1 and 4, 6, and
24 hours after birth
in phase 2. .

After phase 1, the
concentration of
propofol in the
colostrum was 0.17
mcg/ml at four hours
and 0.14 mcg/ml at
eight hours. After
phase 2, the
concentration of
propofol in the
colostrum was 0.54
mcg/ml at 4 hours,
0.036 mcg/ml at 6
hours, and 0.048
mcg/ml at 24 hours.

Because of the low
III
concentration of
propofol in the
colostrum and the low
bioavailability of
propofol, the authors
concluded that
neonatal exposure of
propofol is low.

B

BREASTFEEDING AFTER MATERNAL ANESTHESIA

Citation

Conceptual Framework

(Author, Year, Title, etc...)

(Theoretical basis for
study)

Design/ Method Sample/Setting

51

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
infusion of
propofol started at
0.5 mg/kg/hr and
titrated to effect.
Esener, Z., Sarihasan, B., Güven, H., & Ustün, E.
Collected and analyzed
Nonexperimental 40 healthy pregnant Thiopentone 5
(1992). Thiopentone and etomidate concentrations in colostrum and blood from study
women at term
mg/kg
maternal and umbilical plasma, and in
mothers who required
undergoing
colostrum. British journal of anaesthesia, 69(6), 586– general anesthesia for
Cesarean section
OR
588. https://doi.org/10.1093/bja/69.6.586
cesarean section.

Dodd, S. E., Hunter Guevara, L. R., Datta, P., Rewers- Collected breastmilk
Felkins, K., Baker, T., & Hale, T. W. (2021).
perioperatively and
Dexmedetomidine levels in breast milk: Analysis of
postoperatively from a
breast milk expressed during and after awake
single lactating mother
craniotomy. Breastfeeding Medicine, 16(11), 919–921. receiving
dexmedetomidine for
https://doi.org/10.1089/bfm.2021.0138
awake craniotomy

Yoshimura, M., Kunisawa, T., Suno, M., Sugawara, A.,
Kurosawa, A., Nakanishi, R., Aoki, K., & Toriumi, T.
(2017). Intravenous dexmedetomidine for cesarean
delivery and its concentration in colostrum.
International Journal of Obstetric Anesthesia, 32, 28–
32. https://doi.org/10.1016/j.ijoa.2017.05.002

Collected blood and
breastmilk levels of
precedex in patients
undergoing cesarean
section

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)

Mean concentrations
of thiopentone in
colostrum were 2
mcg/ml at 30
minutes, 0.91 mcg/ml
at 2 hours, and 0.59
Etomidate 0.3
mcg/ml at 9 hours.
mg/kg
Mean concentrations
of etomidate in
colostrum were 79
ng/ml at 30 minutes,
16 ng/ml at 2 hours,
and undetectable at 4
hours. The M:P ratio
of etomidate was 1.2
at 30 minutes after
administration.
Nonexperimental 29 year old lactating Patient was
Breastmilk was
The concentration of
study
woman who
sedated with 45
expressed and
precedex in the
presented for an
mcg of precedex analyzed twice
breastmilk was
awake craniotomy 4 and then placed on intraoperatively and assessed in pg/ml.
weeks post partum an infusion
twice
The highest
between 0.7-1
postoperatively.
concentration found
mcg/kg/hr.
both intraoperatively
and postoperatively
was 89 pg/ml.
Nonexperimental 10 healthy
After cord
study
parturients
clamping 6
presenting for
mcg/kg/hr of
scheduled cesarean precedex was
section between 18- administered
40 years
followed by 0.2-

Thiopental and
etomidate levels
were measured in
maternal plasma,
umbilical venous
plasma, and
colostrum

Blood and colostrum
precedex levels were
collected at 6, 12,
and 24 hours after
precedex
administration.

Six hours after
administration, the
median precedex
concentration in
colostrum was 12.3
pg/m, the median RID
was 0.034%, and the

Level of Quality
evidence of
evidence

Colostrum
II
concentrations
declined rapidly for
thiopentone and
etomidate, but
etomidate was much
quicker. Both
thiopentone and
etomidate are safe for
the nursing mother.

A

Because a typical
III
pediatric dose of
precedex is 0.2-0.7
mcg/kg/hr, and the
bioavailability of
precedex is low, the
amount present in the
breastmilk is negligible
in terms of neonatal
effect.
Maternal sedation
III
using precedex is
unlikely to harm the
nursing infant.

C

B
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Citation

Conceptual Framework

Design/ Method Sample/Setting

(Author, Year, Title, etc...)

(Theoretical basis for
study)

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
0.7 mcg/kg/hr until
peritoneal closure.
Nonexperimental 4 women between After cord
the ages of 24-40
clamping 6
study
presenting for
mcg/kg/hr of
cesarean section
precedex was
administered
followed by 0.20.7 mcg/kg/hr until
peritoneal closure.

Nakanishi, R., Yoshimura, M., Suno, M., Yamamoto, K., Collected blood and
breastmilk levels of
Ito, H., Uchimine, Y., Toriumi, T., Kurosawa, A.,
precedex in patients
Sugawara, A., & Kunisawa, T. (2017). Detection of
dexmedetomidine in human breast milk using liquid undergoing cesarean
section
chromatography–tandem mass spectrometry:
Application to a study of drug safety in breastfeeding
after cesarean section. Journal of Chromatography B,
1040, 208–213.
https://doi.org/10.1016/j.jchromb.2016.11.015

Goma, H. M., Said, R. N., & El-Ela, A. M. (2008). Study
of the newborn feeding behaviors and fentanyl
concentration in colostrum after an analgesic dose of
epidural and intravenous fentanyl in cesarean
section. Saudi medical journal, 29(5), 678–682.

Collected breastmilk levels RCT
of fentanyl in patients who
received IV and epidural
fentanyl

100 multiparas
between the age of
25-35 who had
breastfed before

Major Variables;
definitions

50 patients
received between
150-200 mcg of
fentanyl in their
epidural with
bupivacaine

50 patients
received a spinal
and were
administred 50
mcg of fentanyl IV
after delivery
Steer, P. L., Biddle, C. J., Marley, W. S., Lantz, R. K., & Collected blood and
Nonexperimental 13 health women 2 mcg/kg of
Sulik, P. L. (1992). Concentration of fentanyl in
colostrum from patients study
undergoing
fentanyl was
colostrum after an analgesic dose. Canadian Journal who received fentanyl for
cesarean section of administered to
of Anaesthesia, 39(3), 231–235.
a general anesthetic
a postpartum tubal patients for
https://doi.org/10.1007/bf03008782
ligation
induction in tubal
ligation patients
and after cord
clamping for
cesarean section
patients

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)
median M:P ratio was
less than 1.
Blood and colostrum Six hours after
levels of precedex
administration, the
were measured at 6 average colostrum
and 24 hours.
concentration of
precedex was 15.1
pg/mL. The average
M/P ratio was 0.62
and the average RID
was 0.05%.

Colostrum fentanyl
levels were
measured 45
minutes and 24
hours after birth

At 45 minutes, there
was an average of 0.4
ng/mL in the epidural
fentanyl group and an
average of 0.19
ng/mL in the IV
fentanyl group.

Level of Quality
evidence of
evidence

These findings indicate III
that using
intraoperative
precedex during
cesarean sections is
unlikely to harm the
nursing infant.

C

Using IV or epidural
I
fentanyl in the nursing
mother has low risk of
causing adverse effects.

A

Serum and colostrum The highest colostrum The amount of fentanyl III
fentanyl
concentration was at that crosses into
concentrations were 45 minutse, at a mean breastmilk after a
obtained at 45
concentration of 0.4 typical dose used for
minutes, 2 hours, 4 ng/mL with a serum general anesthesia is
hours, 6 hours, 8
concentration of 0.19 not likely to cause
infant depression.
hours, and 10 hours ng/mL.
after fentanyl
administration.
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Major Variables;
definitions

Outcome
Measurement

Data Analysis

Findings

Level of Quality
evidence of
evidence

(Number,
(What stats used?)
(Statistical findings or
Characteristics,
(Independent
(What scales used –
qualitative findings)
Exclusions, Criteria, variables;
reliability
Attrition, etc...)
Dependent
information – alphas)
variables)
Collected breastmilk
Nonexperimental 10 multigravida
Half of participants Breastmilk
The highest
Because concentrations III
samples from mothers
mother who were received a loading specimens were
concentration of
study
of morphine-6who received meperidine
ASA I/II undergoing dose of opioid (1 obtained at 12, 24, meperidine was an
glucuronide (M6G)
or morphine for
elective cesarean
mg/kg of
36, 48, 72, and 96
average of 1100
were not calculated,
postoperative analgesia
sections
meperidine or 0.1 hours post partum. ng/mL at 2 hours
findings from this study
mg/kg of
The authors
after administration. must be interpreted
morphine), then a calculated the
The highest
with caution.
intravenous PCA
concentration of
concentration of
pump with a six
meperidine,
morphine was an
minute lockout
morphine,
average of 60 ng/mL 4
with either 12.5 mg normeperidine, and hours after
administration.
of meperidine or 1- morphine-31.5 mg of
glucuronide in the
morphine
breastmilk.
Additionally, the
authors calculated
the cumulative dose
of meperidine and
morphine.
Used the Neonatal
RCT
102 parturients who Mothers received a NBAS was used to
Nursing infants
PCA morphine is
I
Behavioral Assessment
underwent
PCA pump with a 6 assess infants for
exposed to morphine superior to PCA
Scale (NBAS) to assess
cesarean section
minute lockout and alertness and
were significantly
meperidine in
infants of nursing and
dose of 12.5-15 mg orientation to human more alert and
treatment of the
bottle-feeding mothers
of meperidine or 1- cues
oriented than infants nursing parturient
who received meperidine
1.5 mg of
who were exposed to
or morphine PCA
morphine. Infants
meperidine and the
were either breast
bottle feeding group.
or bottle fed.
Collected plasma and
breastmilk samples from
mothers who were on a
morphine PCA after
cesarean section

Nonexperimental 7 ASA status I or II Mothers received a Plasma and
patients scheduled 4 mg of morphine breastmilk
study
for cesarean section after delivery and 1 concentrations of
morphine and
mg of morphine
every 10 minutes morphine-6until their visual
glucuronide were
analog scale score obtained.
was less than 3.
Then, a morphine
PCA with a 10

The highest milk to
plasma ratio for
morphine was 0.62
and M6G was 2.73 at
12 hours. The highest
mean morphine
concentration in the
breastmilk was 34
ng/mL at 0 hr. the
highest mean

The amount of
III
morphine and M6G in
the breastmilk was
minute.

B

A
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(Number,
(What stats used?)
Characteristics,
(Independent
(What scales used –
Exclusions, Criteria, variables;
reliability
Attrition, etc...)
Dependent
information – alphas)
variables)
minute lockout
concentration of M6G
with a dose of 1 mg
was 672 ng/mL at 12
and max dose of 20
hours.
mg/4 hours
Nonexperimental 20 ASA status I or II Mothers had a
Plasma and
The highest mean
study
patients scheduled pethidine PCA with breastmilk
absolute dose of
for cesarean section a dose of 20 mg
concentrations of
meperidine was 21
at 37 weeks
and lockout of 20 pethidine and
mcg/kg/day and of
gestation or greater minutes
norpethidine were normeperidine was
measured
22 mcg/kg/day.

Al-Tamimi, Y., Ilett, K. F., Paech, M. J., O’Halloran, S. J., Collected plasma and
& Hartmann, P. E. (2011). Estimation of infant dose
breastmilk levels of
and exposure to pethidine and norpethidine via
pethidine and
breast milk following patient-controlled epidural
norpethidine from
pethidine for analgesia post caesarean delivery.
mothers who were on a
International Journal of Obstetric Anesthesia, 20(2), meperidine PCA after
128–134. https://doi.org/10.1016/j.ijoa.2010.12.004 cesarean section
Borgatta, L., Jenny, R. W., Gruss, L., Ong, C., & Barad, Collected plasma and
Nonexperimental 9 women who
D. (1997). Clinical significance of methohexital,
breastmilk levels of
study
presented for tubal
meperidine, and diazepam in breast milk. The Journal pethidine, methohexital,
sterilization at least
of Clinical Pharmacology, 37(3), 186–192.
and diazepam of mothers
one month after
https://doi.org/10.1002/j.1552-4604.1997.tb04780.x who presented for a
birth
general anesthetic

Major Variables;
definitions

Mothers received
120-150 mg of
methohexital, a
dose of 25 mg of
meperidine, and a
dose of 0-10 mg of
diazepam

Outcome
Measurement

Three sets of blood
and milk samples
were obtained from
each woman

Data Analysis

The highest
methohexital
concentration was 1
one hour after
administration with a
milk concentration of
407 ng/mL, with a
calculated infant
exposure index of 12%.

Findings
(Statistical findings or
qualitative findings)

Level of Quality
evidence of
evidence

As relative infant doses III
of meperidine are very
low, this drug appears
to be safe to administer
to the lactating mother.

B

The amount of drug
III
excreted in the
breastmilk is not of
clinical importance and
does not warrant an
interruption in
breastfeeding.

B

The highest mean
value of meperidine
was 176 ng/mL, with
a calculated infant
exposure index
between 0.5-1.7%.

Ilett, K. F., Paech, M. J., Page-Sharp, M., Sy, S. K.,
Kristensen, J. H., Goy, R., Chua, S., Christmas, T., &
Scott, K. L. (2008). Use of a sparse sampling study

Collected plasma and
breastmilk levels of
tramadol and M1 of

Nonexperimental 75 breastfeeding
mothers who
study
received oral

Mothers received
50-100 mg of

Diazepam levels did
not exceed the lower
limit of the reportable
range at any time
point in the study.
Plasma and
The relative infant
Administration of
breastmilk samples dose of tramadol was tramadol in the
were obtained after 2.24% and M1 was
lactating mother is

III

A
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design to assess transfer of Tramadol and its Odesmethyl metabolite into transitional breast milk.
British Journal of Clinical Pharmacology, 65(5), 661–
666. https://doi.org/10.1111/j.13652125.2008.03117.x

mothers who received
tramadol for analgesia
after cesarean section
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
tramadol on days 2- tramadol every 4-6
4 after cesarean
hours
section

Salman, S., Sy, S. K., Ilett, K. F., Page-Sharp, M., &
Used Ilett et al.’s data set Nonexperimental 75 breastfeeding
Paech, M. J. (2011). Population pharmacokinetic
to create a
study
mothers who
modeling of Tramadol and its O-desmethyl metabolite pharmacokinetic model of
received oral
in plasma and breast milk. European Journal of
tramadol and M1 in
tramadol on days 2Clinical Pharmacology, 67(9), 899–908.
plasma and breastmilk
4 after cesarean
https://doi.org/10.1007/s00228-011-1023-6
section

Mothers received
50-100 mg of
tramadol every 4-6
hours

Outcome
Measurement
(What scales used –
reliability
information – alphas)
the fourth
administration of
tramadol

Plasma and
breastmilk samples
were obtained after
the fourth
administration of
tramadol

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

Level of Quality
evidence of
evidence

0.64%, for a total
unlikely to cause
relative infant dose of adverse effects in the
2.88%.
infant.

Infants of ultra-slow Administration of
III
metabolizers received tramadol in the
an average relative
lactating mother is
dose of 3.07% and the unlikely to cause
infants of ultra-fast
adverse effects in the
metabolizers received infant even if
an average relative
metabolism is altered.
dose of 3.09%.
Edwards, J. E., Rudy, A. C., Wermeling, D. P., Desai, N., Collected plasma and
Nonexperimental 5 healthy,
Mothers received 2 Plasma and
The relative infant
Administration of
III
& McNamara, P. J. (2003). Hydromorphone transfer breastmilk levels from
nonsmoking,
breastmilk samples dose is 0.67%.
intranasal dilaudid is
study
mg of intranasal
into breast milk after intranasal administration.
lactating women who
lactating women
were obtained 2, 4,
unlikely to cause
versed
Pharmacotherapy, 23(2), 153–158.
received intranasal
adverse events in the
between the ages of
6, 8, 12, and 24 hours
https://doi.org/10.1592/phco.23.2.153.32081
dilaudid
infant.
24-32
after administration.
Wolfson, P., Cole, R., Lynch, K., Yun, C., Wallach, J.,
Collected breastmilk from Nonexperimental 4 healthy lactating Mothers received Breastmilk samples The maximum
The relative infant dose III
Andries, J., & Whippo, M. (2021). The
lactating women who
women between
0.5 mg/kg and 1
were obtained 0, 3, amount transferred of ketamine was less
study
pharmacokinetics of ketamine in the breast milk of
received intramuscular
the ages of 21-45
mg/kg of IM
6, 9, and 12 hours
into breastmilk over than 1%, indicating
lactating women: Quantification of ketamine and
ketamine
ketamine
after administration. 12 hours was 24 mcg there is low likelihood
metabolites.
separated by 5
of kertamime and 21 of adverse effects in
https://doi.org/10.22541/au.161325028.80476344/v1
days to 2 weeks
mcg of norketamine. the nursing infant.
Dusci, L. J., Good, S. M., Hall, R. W., & Ilett, K. F.
Collected breastmilk and Case Study
22 year old
The mother was
Plasma and
The highest
The amounts of
V
(1990). Excretion of diazepam and its metabolites in plasma samples from a
polydrug abuser
detoxed over 30
breastmilk samples concentration of
diazepam and its
human milk during withdrawal from combination high lactating woman going
with a 12 month old days with a taper were obtained from diazepam or
metaboiites detected in
dose diazepam and oxazepam. British Journal of
through withdrawal of
son
of diazepam and the mother on days metabolite
the blood were
Clinical Pharmacology, 29(1), 123–126.
diazepam and oxazepam.
oxazepam
14, 15, 23, 25, 28,
throughout the study minimal.
https://doi.org/10.1111/j.1365-2125.1990.tb03612.x Infant plasma drug levels
and 39.
was 300 mcg/L of
were also collected
diazepam in the
breastmilk on day 15.
Plasma samples were
obtained from the
infant on days 14, 28, Diazepam was
and 38.
undetectable in infant
plasma, however
there were low
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B
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)

Collected breastmilk,
Nonexperimental 3 postpartum
maternal plasma, and
study
nursing mothers
infant plasma levels after
nursing mothers received
diazepam

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)

concentration of
metabolites in infant
plasma.
Mothers received Plasma and
The highest maternal
10 mg of diazepam breastmilk
plasma and
three times a day concentrations were breastmilk
for six days
obtained on days 4 concentration of both
and 6
diazepam and nmethyl-diazepam
were found on day six
at a mean of 601
ng/mL and 483 ng/mL
(plasma) and 78
ng/mL and 52 ng/mL
(milk).

Level of Quality
evidence of
evidence

The authors concluded III
that diazepam should
not be consumed by
the nursing mother.

The highest infant
plasma
concentrations were
found on day four
with 172 ng/mL of
diazepam and 283
ng/mL of n-methyldiazepam.
Koitabashi, T., Satoh, N., & Takino, Y. (1997).
Maternal plasma and
Case Study
A 20 year old
6 mg of IV
Plasma and
The highest
Midazolam is unlikely
Intravenous midazolam passage into breast milk.
lactating woman
midazolam was
breastmilk
concentration of
to cause adverse
blood concentrations were
Journal of Anesthesia, 11(3).
presenting for
administered for concentrations were midazolam, 12 ng/mL, effects in the nursing
measured after IV
https://doi.org/10.1007/s0054070110242
laparoscopic
induction of
measured 1, 2, 4, 6, was found 1 hour
infant
midazolam administration
cholecystectomy
general anesthesia and 24 hours after after administration.
midazolam
administration
Matheson, I., Lunde, P. K., & Bredesen, J. E. (1990).
Collected blood and
Nonexperimental 12 lactating women 15 mg of oral
Plasma and
Average breastmilk Midazolam is unlikely
Midazolam and nitrazepam in the Maternity Ward:
breastmilk levels of
study
in a postpartum unit midazolam was
breastmilk
concentrations of
to cause adverse
Milk concentrations and clinical effects. British Journal mothers who received
administered as a concentrations were midazolam were 3.3 effects in the nursing
of Clinical Pharmacology, 30(6), 787–793.
midazolam
sleep aid
obtained 7 hours
ng/mL
infant
https://doi.org/10.1111/j.1365-2125.1990.tb05443.x
after administration
for 6 days after birth
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
Summerfield, R. J., & Nielsen, M. S. (1985). Excretion Collected blood and
Nonexperimental 4 lactating women 3.5 mg of oral
of Lorazepam into breast milk. British Journal of
breastmilk levels of
presenting for post- lorazepam was
study
Anaesthesia, 57(10), 1042–1043.
mothers who received
partum sterilization administered 2
https://doi.org/10.1093/bja/57.10.1042-a
lorazepam
hours before
surgery
Whitelaw, A., Mcfadyen, I., & Cummings, A. (1981).
Collected breastmilk from Case study
A postpartum
2.5 mg of oral
Effect of maternal lorazepam on the Neonate. BMJ, a postpartum mother who
woman receiving
lorazepam was
282(6280), 1973–1974.
received lorazepam twice
lorazepam
administered twice
https://doi.org/10.1136/bmj.282.6280.1973-c
daily
a day for five days

Madadi, P., Koren, G., Cairns, J., Chitayat, D., Gaedigk, Analyzed the maternal
Case study
A., Leeder, J. S., Teitelbaum, R., Karaskov, T., & Aleksa, breastmilk and
K. (2007). Safety of codeine during breastfeeding:
postmortem blood
fatal morphine poisoning in the breastfed neonate of concentrations of a infant
a mother prescribed codeine. Canadian Family
who died from morphine
Physician Medecin de Famille Canadien, 53(1), 33–35 overdose after maternal
codeine use.
************RETRACTED in 2021**********.
Zipursky, J., & Juurlink, D. N. (2020). The implausibility Discusses the infant death Literature review
of neonatal opioid toxicity from breastfeeding. Clinical from maternal opioid use
in the “Toronto case”
Pharmacology &Therapeutics, 108(5), 964–970.
https://doi.org/10.1002/cpt.1882

A newborn with
unremarkable birth
history expires on
DOL 11

The mother of the
infant took Tylenol
3 (codeine and
acetaminophen)
for postpartum
pain control

Reviewed articles Na
describing neonatal
depression or
sedation from
maternal codeine
use

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)

Level of Quality
evidence of
evidence

Plasma and
Participants had an
breastmilk levels of average breastmilk
lorazepam were
concentration of 8.5
measured 4 hours
ng/mL.
after administration
Breastmilk levels of The participant’s
lorazepam were
breastmilk contained
measured on day five 12 ng/mL/.
of treatment

The amount of
III
lorazepam that crosses
into breastmilk is very
low, leading to minimal
risk for the infant.
If the infant consumed V
200 mL/kg/day, the
resulting infant dose
would be 2.6
mg/kg/day, a negligible
dose of lorazepam.

B

Post mortem and
Frozen breast milk
frozen expressed
contained 87 ng/mL
breast milk morphine of morphine and
levels were obtained infant blood levels
were 70 ng/mL

Because a therapeutic V
serum concentration of
morpgine in an infant is
~10 ng/mL, authors
concluded the infant
died from morphine
overdose

B

Na

Although the results
V
from the Toronto case
are unexplainable using
appropriate
pharmacokinetic
models, there are still
multiple instances in
the literature that
indication maternal
codeine use and cause
neonatal sedation and
depression. These
symptoms typically
resolve with the
removal of codeine or
withholding of
breastmilk.

A
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)
Willmann, S., Edginton, A. N., Coboeken, K., Ahr, G., Describes the
Nonexperimental Created a PBPK
Na
&Lippert, J. (2009). Risk to the breast-fed neonate
development of a
model of both the
study
mother and infant
from codeine treatment to the mother: A quantitative pharmacokinetic model to
to determine
mechanistic modeling study. Clinical Pharmacology & estimate morphine
exposure and clearance in
metabolism and
Therapeutics, 86(6), 634–643.
the nursing infant of a
https://doi.org/10.1038/clpt.2009.151
excretion of codeine
mother who takes codeine
and morphine

Madadi, P., Ross, C. J. D., Hayden, M. R., Carleton, B.
C., Gaedigk, A., Leeder, J. S., & Koren, G. (2008).
Pharmacogenetics of neonatal opioid toxicity
following maternal use of codeine during
breastfeeding: A case–control study. Clinical
Pharmacology & Therapeutics, 85(1), 31–35.
https://doi.org/10.1038/clpt.2008.157

Compare genetic
Quasicharacteristics of nursing experimental
mother and baby dyads
study
that did or did not exhibit
CNS depression after
maternal codeine
administration

72 mother-child
pairs who were
counseled by the
MotherRisk
program between
2004-2007 and
were reachable by
telephone

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

Na

Mother’s codeine and III
morphine clearance
and infant’s morphine
clearance are the most
important determinant
of morphine
accumulation in the
neonate. Additionally,
CYP3A4 inhibitors
inhibit the breakdown
of codeine, leaving
more available to
convert to morphine.

(What scales used –
reliability
information – alphas)
Na

Level of Quality
evidence of
evidence

A worst case scenario
of an ultra-rapid
metabolizer mother
with a codeine dose of
2.5 mg/kg/day,
efficient morphine
crossover into the
breastmilk, and lack of
neonatal elimination,
the infant’s morphine
blood level would be 54
mcg/L, almost four
times higher than the
therapeutic dose.
Infants who
CNS depression was Infants exhibiting
Mothers of infants who II
experienced CNS defined as parental signs of CNS
were CNS depressed
reports of sedation depression while
took significantly higher
depression
or abnormal
breastfeeding from a doses of codeine
breathing in the
mother who has used
Infants who did not
infant.
codeine were
experience CNS
Mothers of
compared to infants
depression
symptomatic infants
who did not exhibit
were 6x more likely to
CNS depression.
be CYP2D6
Genotype
Factors compared
ultrametabolizers than
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Examined if postnatal
maternal codeine
consumption was
associated with adverse
neonatal outcomes
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)

Retrospective
cohort study

15608 Women
women who
living in Ontario,
received a
Canada between
prescription for
the years 1998-2008 codeine within 7
who had singleton days of discharge
pregnancies and
after childbirth
were greater than
16 years old
women who did
not receive a
prescription for
codeine after
childbirth

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

include: daily
maternal codeine
dose per kilo- gram
body weight, and
CYP2D6 and UGT2B7
genotype.

mothers of
asymptomatic infants

(What scales used –
reliability
information – alphas)

Level of Quality
evidence of
evidence

Because of
accumulation of active
metabolites, neonatal
risk is increased with
prolonged codeine use
Admission of the
There were no
Children of mothers
II
neonate to a hospital statistical differences prescribed codeine
within 30 days
in readmission,
were at no greater risk
dehydration, injury, of adverse events than
arrival by ambulance, children of mothers
Admission of the
or resuscitation
who weren’t prescribed
neonate for
between the two
codeine
dehydration within
groups.
30 days

A

Admission of the
neonate for injury
within 30 days
Admission to the
hospital via
ambulance
Hospitalization with
resuscitation or
assisted ventilation

Lam, J., Kelly, L., Ciszkowski, C., Landsmeer, M. L. A.,
Nauta, M., Carleton, B. C., Hayden, M. R., Madadi, P.,
& Koren, G. (2012). Central Nervous System
Depression of neonates breastfed by mothers
receiving oxycodone for postpartum analgesia. The

Quantified incidence of
CNS depression in
neonates breastfed by
mothers taking codeine,
oxycodone, or Tylenol

Retrospective
Cohort Study

533 breastfeeding Mothers taking
mother infant pairs codeine,
oxycodone, or
Tylenol

Death
CNS depression
Reversibility of CNS
depression on
cessation of

Infants of oxycodone
consuming mothers
had a 21% incidence
of CNS depression

Both maternal codeine II
and oxycodone are
related to increased
CNS depression in the
nursing infant

A
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)

Journal of Pediatrics, 160(1).
https://doi.org/10.1016/j.jpeds.2011.06.050

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)
breastfeeding or
opioid usage

Level of Quality
evidence of
evidence

Infants of codeine
consuming mothers
had a 16% incidence
of CNS depression.
Infants of Tylenol
consuming mothers
had a 0.5% incidence
of CNS depression.

Kelly, L. E., Chaudhry, S. A., Rieder, M. J., ‘t Jong, G.,
Moretti, M. E., Lausman, A., Ross, C., Berger, H.,
Carleton, B., Hayden, M. R., Madadi, P., & Koren, G.
(2013). A clinical tool for reducing central nervous
system depression among neonates exposed to
codeine through breast milk. PLoS ONE, 8(7).
https://doi.org/10.1371/journal.pone.0070073

Evaluated the
effectiveness of
breastfeeding guidelines
for mothers taking
codeine at improving
neonatal safety

Wischnik, A., Manth, S. M., Lloyd, J., Bullingham, R., & Establish the extent in
Thompson, J. S. (1989). The excretion of Ketorolac
which ketorolac is
tromethamine into breast milk after multiple oral
excreted into breastmilk
dosing. European Journal of Clinical Pharmacology,
36(5), 521–524. https://doi.org/10.1007/bf00558080

Nonexperimental 237 breastfeeding
study
women taking
codeine after
cesarean section

Mothers received
guidelines for
breastfeeding
while taking
codeine

Almost all mothers
reported resolution of
symptoms with
cessation of
breastfeeding or
opioid use
Duration of codeine There was a 2%
Implementation of
III
use
incidence of neonatal breastfeeding
sedation
guidelines greatly
increases the safety of
Occurrence of
codeine in the nursing
neonatal sedation
Women who reported
mother
neonatal CNS
depression were
occurence of
taking codeine for > 4
maternal adverse
days
reactions

Maternal adverse
response did not
correlate with
sedation
Nonexperimental 10 postpartum
Patient received 10 Maternal plasma and The maximum
study
women who
mg of oral
Breastmilk
concentration in
required an
ketorolac 4x a day concentrations were breastmilk detected
analgesic and were for three days
collected during the was 7.9 ng/mL.
abstaining from
two dosing days and
breastfeeding
one day after

The risk of adverse
events is low in
neonates of mothers
taking Toradol.

III

A

B

BREASTFEEDING AFTER MATERNAL ANESTHESIA

Citation

Conceptual Framework

(Author, Year, Title, etc...)

(Theoretical basis for
study)

61

Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)

Outcome
Measurement

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

(What scales used –
reliability
information – alphas)

Level of Quality
evidence of
evidence

completion of
The highest M:P ratio
medication regimen of ketorolac detected
was 0.037

Bitzen, P.O., Gustafsson, B., Jostell, K. G., Melander,
A., & Wahlin-Boll, E. (1981). Excretion of paracetamol
in human breast milk. European Journal of Clinical
Pharmacology, 20(2), 123–125.
https://doi.org/10.1007/bf00607148

Assess the amount of
Nonexperimental 3 lactating women
Tylenol into breastmilk of study
who stopped
mothers who took oral
breastfeeding
tylenol

Women received
one dose of 500
mg of oral
acetaminophen

Berlin, C. M., Jr, Yaffe, S. J., & Ragni, M. (1980).
Disposition of acetaminophen in milk, saliva, and
plasma of lactating women. Pediatric pharmacology
(New York, N.Y.), 1(2), 135–141.

Assessed Tylenol
Nonexperimental 12 nursing mothers Mothers received
concentrations in saliva, study
one dose of 650
breastmilk, and plasma of
mg of oral Tylenol
nursing mothers.

Notarianni, L. J., Oldham, H. G., & Bennett, P. N.
(1987). Passage of paracetamol into breast milk and
its subsequent metabolism by the neonate. British
journal of clinical pharmacology, 24(1), 63–67.
https://doi.org/10.1111/j.1365-2125.1987.tb03137.x

Assessed Tylenol and
Nonexperimental 4 nursing mother
metabolite concentrations study
and baby pairs
in maternal plasma,
breastmilk, and infant
urine.

the infant may
receive an adjusted
daily dose of 0.4%of
the maternal dose
Maternal plasma and The maximum
breastmilk
Breastmilk
concentrations were concentration of
measuared before Tylenol was found
two hours after
medication
administration and administration. The
average
2,4,6,8,10, and 12
concentration of
hours after
Tylenol in breastmilk
administration.
was 4.4 mcg/mL.
The milk plasma ratio
was 0.76.
Peak breastmilk
concentration of 15
mcg/mL was found
between 1-2 hours.

Saliva and milk
concentrations of
Tylenol were
obtained at 0, 0.25,
0.5, 0.75, 1, 2, 3, 5, 8,
12, and 24 hours
after maternal
dosing.
Mothers received 1 Blood and milk
The average peak
gram of Tylenol by samples (all from the Tylenol breastmilk
mouth
same breast) were concentration was
obtained from the
10.3 mcg/mL.
mother every 30
minutes for 3.5
The average Tylenol
hours. At the end of
milk concentration
the 3.5 hours, the
was 6.1 mg/mL.

The amount of Tylenol III
that crossed over into
the breastmilk was
negligible, not
indicating a need for
breastfeeding cessation
while taking Tylenol.

B

Tylenol used in usual III
analgesic dosing for the
mother does not
appear to increase risk
to the breastfeeding
infant.

B

The amount of Tylenol III
received by the infant
is negligible.

B
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Design/ Method Sample/Setting

Major Variables;
definitions

(Number,
Characteristics,
(Independent
Exclusions, Criteria, variables;
Attrition, etc...)
Dependent
variables)

Outcome
Measurement
(What scales used –
reliability
information – alphas)
other breast was
emptied into a
different container
and breastmilk
concentration was
assessed.

****still need to fix level and quality of evidence for some articles*****

Data Analysis

Findings

(What stats used?)

(Statistical findings or
qualitative findings)

Level of Quality
evidence of
evidence
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Appendix B
IRB Exemption Statement
Conversation between IRB Chair, Dr. Noam Shpancer and Dr. John Chovan, Department of
Nursing Chair.
From: Shpancer, Noam <nshpancer@otterbein.edu>
Sent: Wednesday, October 13, 2021 9:44 AM
To: Chovan, John <jchovan@otterbein.edu>
Subject: Re: IRB and DNP Projects
John: The way I see it, a project is not subject to IRB review unless and until it collects data from
human participants. So, I agree with you that these projects will not need IRB approval until
someone decides to implement them for data collection, at which point that person may apply
for IRB approval.
Thanks, Noam.
From: Chovan, John <jchovan@otterbein.edu>
Sent: Wednesday, October 13, 2021 9:10 AM
To: Shpancer, Noam <nshpancer@otterbein.edu>
Subject: IRB and DNP Projects
Good morning, Noam,
I could use some advice -- maybe a conversation -- about the Doctor of Nursing Practice final
scholarly projects and submitting for IRB approval. The projects parameters from our
accreditors for some of the projects have changed. The list of acceptable projects now includes
the option of writing a plan for a project that is not implemented. So, it can effectively stop at
the proposal stage, and then these projects can be available for a future student to implement
if someone has that interest. I have at least two questions.
1. The IRB Guidelines states "Research means a systematic investigation, including
research development, testing, and evaluation, designed to develop or contribute
to generalizable knowledge." Most of these projects are not intended to develop or
contribute to generalizable knowledge. They are clinical change projects that are
intended to eventually change a clinical practice of health care professionals
(humans) in one identified setting. They have the possibility of contributing to
generalizable knowledge in that each would be an instance of a clinical change that,
if implemented in other places by others, could eventually be generalized. But that
is not the primary intent of the projects. Would they be considered research? I
think they would not.
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2. If indeed they are considered research and should be submitted for review by the
IRB, at what point in the process should IRB approval be obtained? I would think
that although implementation is not part of the initial project, review by IRB would
be helpful to the original team in shaping their project plan. Yet if this proposal is
not going to be implemented, then the approval to move forward would be
moot. But if a second team eventually reads the proposal and wants to implement
it, would they be the ones seeking IRB approval?
If you would prefer that we talk in real time, I am open to that. Or perhaps you could visit one
of our faculty meetings for a discussion?
Thank you.
Best,
John
John D. Chovan, PhD, DNP, RN, CNP, CNS, PMHNP-BC
Associate Professor & Chair, Department of Nursing
Chief Nurse Administrator
Otterbein University

"A comprehensive institution with a strong liberal arts base"
jchovan@otterbein.edu; 614-823-1526, voice; he/him/his
"The world is starved for grace. If we are going to work at restoring fellowship and reaching people, we need grace
now more than ever.”
- Pastor John Swadley, Forest Park Baptist Church, Joplin, Missouri
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Appendix C
JHNEBP Model Permission
LEARNING SYSTEM HOME

COURSE CATALOG

CONTACT US

JOIN OUR MAILING LIST

IJHN WEBSITE

Home » Johns Hopkins EBP Model and Tools- Permission

JOHNS HOPKINS EBP MODEL AND TOOLS- PERMISSION
Johns Hopkins Nursing
CenterforEvidence-BasedPractice

Thank you for your submission. We are happy to give you permission to use the Johns Hopkins Evidence-Based Practice model and
tools in adherence of our legal terms noted below:

• You may not modify the model or the tools without written approval from Johns Hopkins.
• All reference to source forms should include "©The Johns Hopkins Hospital/The Johns Hopkins University."
• The tools may not be used for commercial purposes without special permission.
If interested in commercial use or discussing changes to the tool, please email _
ijb.o.@jhmi.edu.

Downloads:
JHEBP Tools-Printable Version
JHEBP Tools-Electronic Version
?O?? IHFRP Tnnl~- PrintnhlF> VF>r~inn
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Appendix D
Breastfeeding After Maternal Anesthesia Knowledge and Confidence Assessment
1. In general, when is it safe for a mother to resume breastfeeding after surgery?
a. Immediately
b. Once she is awake and alert
c. Four hours after extubation
d. 24 hours after surgery
2. What induction medications are safe to use in the breastfeeding mother?
a. Propofol
b. Etomidate
c. Ketamine
d. Dexmedetomidine
e. All of the above
3. Which medication is contraindicated for nursing mothers?
a. Propofol
b. Midazolam
c. Codeine
d. Toradol
4. What medication has inadequate evidence for the use in lactating mothers?
a. Hydromorphone
b. Fentanyl
c. Acetaminophen
d. Etomidate
5. In general, how long should breastfeeding women “pump and dump” after anesthesia?
a. 24 hours
b. 36 hours
c. 12 hours
d. Pumping and dumping is unnecessary for most anesthetics
6. Which opioid is safest for use in the lactating mother?
a. Fentanyl
b. Codeine
c. Tramadol
d. Meperidine
7. Which benzodiazepine should be administered with caution in the nursing mother?
a. Diazepam
b. Lorazepam
c. Midazolam
8. What non-opioid analgesic is safe to use in the nursing mother?
a. Acetaminophen
b. Ketorolac
c. All of the above
9. What types of medications are the most dangerous for the nursing mother?
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a. Pro-drugs
b. Active drugs
10. What online resource has the most up to date resources detailing medication safety in
the lactating mother?
a. Lactmed
b. Google
c. UpToDate
d. WebMD
11. How would you rate your confidence in providing postoperative breastfeeding
recommendations to the lactating mother?
a. Excellent
b. Above Average
c. Average
d. Below Average
e. Poor

